US11124776B2 - Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof - Google Patents

Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof Download PDF

Info

Publication number
US11124776B2
US11124776B2 US16/444,576 US201916444576A US11124776B2 US 11124776 B2 US11124776 B2 US 11124776B2 US 201916444576 A US201916444576 A US 201916444576A US 11124776 B2 US11124776 B2 US 11124776B2
Authority
US
United States
Prior art keywords
virus
bacterial
syn
site
payload
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/444,576
Other languages
English (en)
Other versions
US20190390175A1 (en
Inventor
Antoine DECRULLE
Xavier DUPORTET
Igor STZEPOURGINSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eligo Bioscience
Original Assignee
Eligo Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eligo Bioscience filed Critical Eligo Bioscience
Assigned to Eligo-Bioscience reassignment Eligo-Bioscience ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DECRULLE, Antoine, STZEPOURGINSKI, Igor, DUPORTET, Xavier
Publication of US20190390175A1 publication Critical patent/US20190390175A1/en
Priority to US17/406,437 priority Critical patent/US11952594B2/en
Assigned to ELIGO BIOSCIENCE reassignment ELIGO BIOSCIENCE CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME AND ADDRESS PREVIOUSLY RECORDED AT REEL: 050582 FRAME: 0460. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: DECRULLE, Antoine, STZEPOURGINSKI, Igor, DUPORTET, Xavier
Application granted granted Critical
Publication of US11124776B2 publication Critical patent/US11124776B2/en
Priority to US18/598,495 priority patent/US20240209326A1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/73—Expression systems using phage (lambda) regulatory sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/202—Pseudochromosomes, minichrosomosomes of bacteriophage origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This application includes an electronically submitted sequence listing in .txt format.
  • the .txt file contains a sequence listing entitled “2643-10_ST25.txt” created on Sep. 9, 2019 and is 4,739 bytes in size.
  • the sequence listing contained in this .txt file is part of the specification and is hereby incorporated by reference herein in its entirety.
  • the invention relates to the field of molecular biology and particularly to the delivery of a payload by bacterial delivery vehicle. More specifically, the present invention concerns the encapsulation and the delivery of a plasmid by bacterial virus particles.
  • Bacterial viruses are small viruses displaying the ability to infect and kill bacteria while they do not affect cells from other organisms. Initially described almost a century ago by William Twort, and independently discovered shortly thereafter by Felix d'Herelle, more than 6000 different bacterial viruses have been discovered so far and described morphologically. The vast majority of these viruses are tailed while a small proportion are polyhedral, filamentous or pleomorphic. They may be classified according to their morphology, their genetic content (DNA vs. RNA), their specific host, the place where they live (marine virus vs. other habitats), and their life cycle.
  • phages display different life cycles within the bacterial host: lytic, lysogenic, pseudo-lysogenic, and chronic infection.
  • Lytic phages once their DNA injected into their host, replicate their own genome and produce new viral particles at the expense of the host. Indeed, they cause lysis of the host bacterial cell as a normal part of the final stage of their life cycles to liberate viral particles.
  • Temperate phages also termed temperate phages
  • temperate phages can either replicate by means of the lytic life cycle and cause lysis of the host bacterium, or they can incorporate their DNA into the host bacterial DNA and become non-infectious prophages (lysogenic cycle).
  • lytic phages are chosen for phage therapy.
  • phage cocktail is composed of at least 3 phages, up to 10 phages in some cases. Combining phages permit to increase the host range of the drug by combining each individual phage host range. Because the different phages have different host receptors, it also reduces the chance that, through mutation of a receptor, resistant bacterium arises. Phage cocktail is therefore a combination of different phages, each one of them encoding different proteins that will lead to the death of the host.
  • each phage can kill the cell in a different way (degrading DNA, bursting the cell, hijacking molecular machinery, etc.).
  • each phage genome is contained in different phage particles targeting different receptors. This turns out to be regulatory difficult to get approved because of its complexity.
  • packaged phagemids (viral particle where phage genome is replaced by a plasmid of interest) allows to have a defined and control way of killing the host.
  • Example of packaged phagemids encoding CRISPR-Cas9 or toxins have shown promising results in killing targeted bacterial population (Bikard et al., 2012 , Cell Host & Microbe 12, 177-186; Jiang et al., 2013 , Nat Biotechnol 31, 233-239; Krom et al., 2015 , Nano Letters 15, 4808-4813; Bikard et al, 2014 , Nat Biotech 11, Vol. 32, Citorik, R et al, 2014 , Nat Biotech 11, Vol. 32).
  • WO2008/157515 relates to the cloning of genomic librairies using phage encapsidation mechanisms.
  • encapsidation initiation sites PIS
  • PIS encapsidation initiation sites
  • the DNA encapsidated is then purified, ligated with a cohesive end and re-encapsidated and cloned into a bacterial strain for further sequencing.
  • this document discloses a plasmid pDW7 ( FIG. 5 ) comprising the encapsidation sites cos and pac.
  • WO2008/157515 has nothing in common with the purpose of the present invention. Indeed, the method described in this document will never lead to the encapsidation in different delivery vehicles and pDW7 has not been designed for and does not code for the expression of a protein of interest into the target bacteria.
  • a first phagemid cocktail or mixture has been developed based on a single payload containing at least 2 orthogonal packaging sites, allowing its packaging into at least two different bacterial delivery vehicles.
  • the invention concerns a pharmaceutical composition
  • a pharmaceutical composition comprising at least two different bacterial delivery vehicles into which the same payload is packaged.
  • payload comprises a nucleic acid sequence of interest under the control of a promoter and at least two orthogonal bacterial virus packaging sites that allow packaging of said payload into said at least two different bacterial delivery vehicles.
  • the at least two orthogonal bacterial virus packaging sites are at least two different cos sites, at least two different pac sites or at least two different concatemer junction sites.
  • the at least two orthogonal bacterial virus packaging sites are at least one cos site and at least one pac site, at least one cos site and at least one concatemer junction site, at least one pac site and at least one concatemer junction site, or at least one cos site, at least one pac site and at least one concatemer junction site.
  • the at least two orthogonal bacterial virus packaging sites are selected in the group consisting of ⁇ cos site, P4 cos site, SPP1 pac site, P1 pac site, T1 pac site, mu pac site, P22 pac site, ⁇ 8 pac site, Sf6 pac site, 149 pac site, T7 concatemer junction, and A1 122-concatemer junction.
  • the at least two orthogonal bacterial virus packaging sites comprising ⁇ cos site and P4 cos site, or ⁇ cos site, P4 cos site and P1 pac site, or ⁇ cos site, P4 cos site and T7 concatemer junction, or ⁇ cos site, P4 cos site, P1 pac site and T7 concatemer junction.
  • the nucleic sequence of interest of the payload according to the invention can be selected from the group consisting of a Cas nuclease, a Cas9 nuclease, a guide RNA, a single guide RNA (sgRNA), a CRISPR locus, a toxin, a gene expressing an enzyme such as a nuclease or a kinase, a TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a membrane protein, a structural protein, a secreted protein, a gene expressing resistance to an antibiotic or to a drug in general, a gene expressing a toxic protein or a toxic factor, and a gene expressing a virulence protein or a virulence factor, or any combination thereof.
  • the nucleic sequence of interest may particularly be an encoding element(s) of the CRISPR/Cas system for the reduction of gene expression or inactivation of a gene selected from the group consisting of an antibiotic resistance gene, virulence factor or protein gene, toxin factor or protein gene, a gene expressing a bacterial receptor, a membrane protein, a structural protein, a secreted protein, and a drug resistance gene, or any of their combination thereof.
  • the bacterial delivery vehicles according to the invention can particularly be bacterial viruses, preferably bacterial viruses selected from the group consisting of BW73, B278, D6, D108, E, E1, E24, E41, FI-2, FI-4, FI-5, HI8A, Ff18B, i, MM, Mu, 025, PhI-5, Pk, PSP3, P1, P1D, P2, P4, S1, W ⁇ , ⁇ K13, ⁇ 1, ⁇ 2, ⁇ 7, ⁇ 92, 7 A, 8 ⁇ , 9 ⁇ , 18, 28-1, 186, 299, HH- Escherichia (2), AB48, CM, C4, C16, DD-VI, E4, E7, E28, FI1, FI3, H, H1, H3, H8, K3, M, N, ND-2, ND-3, ND4, ND-5, ND6, ND-7, Ox-I, Ox-2, Ox-3, Ox-4, Ox-5, Ox-6, PhI-I, RB42, RB43,
  • the bacterial delivery vehicles are capable of targeting at least two different bacteria and of introducing the payload into the bacteria.
  • the bacterial delivery vehicles are capable of targeting the same bacteria and of introducing the payload into these bacteria.
  • the pharmaceutical composition according to the invention comprise the disclosed bacterial delivery vehicles and at least one additional active ingredient, for instance a prebiotic and/or a probiotic and/or an antibiotic, and/or another antibacterial or antibiofilm agent, and/or any agent enhancing the targeting of the bacterial delivery vehicle to a bacteria and/or the delivery of the payload into a bacteria.
  • additional active ingredient for instance a prebiotic and/or a probiotic and/or an antibiotic, and/or another antibacterial or antibiofilm agent, and/or any agent enhancing the targeting of the bacterial delivery vehicle to a bacteria and/or the delivery of the payload into a bacteria.
  • the pharmaceutical composition according to the invention may be for use as a medicament.
  • the pharmaceutical composition may be used for in-situ bacterial production of a compound of interest, preferably said compound of interest being produced inside the targeted bacteria, secreted from the targeted bacteria or expressed on the surface of the targeted bacteria.
  • the compound of interest can be an antigen expressed on the surface of the targeted bacteria for prophylactic and/or therapeutic vaccination.
  • the pharmaceutical composition according to the invention may be for use in the treatment of a disorder or disease caused by a bacterium, preferably by an antibiotic-resistant bacterium, such as an infection, preferably a bacterial infection, inflammatory diseases, auto-immune diseases, cancers, metabolic disorders and/or brain disorders.
  • a bacterium preferably by an antibiotic-resistant bacterium, such as an infection, preferably a bacterial infection, inflammatory diseases, auto-immune diseases, cancers, metabolic disorders and/or brain disorders.
  • the pharmaceutical composition according to the invention may also be for use in the prevention of a disorder or a disease caused by a bacterium found in a subject, preferably by an antibiotic-resistant bacterium, such as an infection, preferably a bacterial infection, inflammatory diseases, auto-immune diseases, cancers, metabolic disorders and/or brain disorders.
  • a disorder or a disease caused by a bacterium found in a subject preferably by an antibiotic-resistant bacterium, such as an infection, preferably a bacterial infection, inflammatory diseases, auto-immune diseases, cancers, metabolic disorders and/or brain disorders.
  • the invention also concerns a payload comprising a nucleic acid sequence of interest under the control of a promoter and at least two orthogonal bacterial virus packaging sites that allow packaging of the payload into said at least two different bacterial delivery vehicles.
  • payload may be a plasmid.
  • the invention finally concerns a bacterial delivery vehicle comprising the payload according to the invention.
  • bacterial delivery vehicle may be a bacterial virus particle.
  • FIG. 1 Concentration of phagemid particles produce from the different lysogenes.
  • FIG. 2 Data from three independent phagemids production.
  • the present invention relates to a payload suitable to be packaged into at least two different bacterial delivery vehicles.
  • This payload comprises at least two orthogonal bacterial viruses packaging sites that allow packaging of the payload into at least two different bacterial delivery vehicles.
  • the advantage is to be able to deliver the same payload to target cells by at least two different bacterial delivery vehicles. Then, it allows the preparation of a pharmaceutical or veterinary composition comprising at least two different bacterial delivery vehicles, each bacterial delivery vehicle having the same payload.
  • the person skilled in the art will be able to select the most appropriate bacterial delivery vehicle for each case and to prepare the selected bacterial delivery vehicle with the packaged payload.
  • the present disclosure relates to a bacterial delivery vehicle comprising such a payload packaged into the bacterial delivery vehicle. It relates to a composition, especially a pharmaceutical or veterinary composition, comprising at least two different bacterial delivery vehicles, the bacterial delivery vehicles comprising the same payload.
  • It also relates to a bacterial cell comprising such a payload, in particular bacterial cells capable of producing a bacterial delivery vehicle comprising such a payload, and to a method for producing such a bacterial delivery vehicle.
  • the present disclosure relates to the use of the bacterial delivery vehicle comprising such a payload or the composition, especially a pharmaceutical or veterinary composition, comprising at least two different bacterial delivery vehicles, the bacterial delivery vehicles comprising the same payload as a medicament, especially in the treatment of a disorder or disease, in particular caused by a bacterium.
  • a kit comprising a payload as defined herein, optionally a satellite phage and/or a helper phage to promote the packaging of the payload in a delivery vehicle, such as a bacterial virus particle, or the structural and functional proteins necessary to promote an in vitro packaging of the payload in a bacterial virus particle, and optionally bacterial cells suitable for packaged payload production.
  • a delivery vehicle such as a bacterial virus particle, or the structural and functional proteins necessary to promote an in vitro packaging of the payload in a bacterial virus particle, and optionally bacterial cells suitable for packaged payload production.
  • the bacterial delivery vehicles preferably the bacterial virus particle, are prepared from bacterial virus, in particular bacteriophages.
  • the bacterial viruses are chosen in order to be able to introduce the payload into the targeted bacteria.
  • nucleic acid and “nucleic acid sequence” are equivalent and refer to a polymeric form of nucleotide of any length, preferably to a sequence of at least two nucleotides covalently linked together which can be single-stranded or double-stranded or contains portion of both single-stranded and double-stranded sequence.
  • Nucleic acids e.g., components, or portions of the nucleic acids
  • Engineered nucleic acids include recombinant nucleic acids and synthetic nucleic acids. Nucleic acids can be in the form of a circular sequence or a linear sequence or a combination of both forms.
  • the nucleic acid can be DNA, both genomic or cDNA, or RNA or a combination of both.
  • the nucleic acid may contain any combination of deoxyribonucleotides and ribonucleotides, and any combination of bases. Any combination of the above features of a nucleic acid is also encompassed by the present invention.
  • the term “gene” can be a genomic gene comprising transcriptional and/or translational regulatory sequences and/or a coding region and/or non-translated sequences (e.g., introns, 5′- and 3′-untranslated sequences and regulatory sequences).
  • the coding region of a gene can be a nucleotide sequence coding for an amino acid sequence or a functional RNA, such as tRNA, rRNA, catalytic RNA, siRNA, miRNA and antisense RNA.
  • a gene can also be an mRNA or cDNA corresponding to the coding regions (e.g. exons and miRNA) optionally comprising 5′- or 3′ untranslated sequences linked thereto.
  • a gene can also be an amplified nucleic acid molecule produced in vitro comprising all or a part of the coding region and/or 5′- or 3′-untranslated sequences linked thereto.
  • Polypeptides described herein may be composed of standard amino acids (i.e., the 20 L-alpha-amino acids that are specified by the genetic code, optionally further including selenocysteine and/or pyrrolysine). Polypeptides may comprise one or more non-standard amino acids. Non-standard amino acids can be amino acids that are found in naturally occurring polypeptides, e.g., as a result of post-translational modification, and/or amino acids that are not found in naturally occurring polypeptides. Polypeptides may comprise one or more amino acid analogues known in the art. Beta-amino acids or D-amino acids may be used.
  • polypeptides may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a fatty acid group, a linker for conjugation, functionalization, etc.
  • a polypeptide that has a non-polypeptide moiety covalently or non-covalently associated may still be referred to as a “polypeptide”.
  • Polypeptides may be purified from natural sources, produced in vitro or in vivo in suitable expression systems using recombinant DNA technology, synthesized through chemical means such as conventional solid phase peptide synthesis and/or using methods involving chemical ligation of synthesized peptides.
  • polypeptide sequence or “protein sequence” or “amino acid sequence” as used herein can refer to the polypeptide material itself and/or to the sequence information (i.e. the succession of letters or three letter codes used as abbreviations for amino acid names) that biochemically characterizes a polypeptide.
  • heterologous in the context of a nucleic acid construct (payload, plasmid, vector or cargo) indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature.
  • a nucleic acid is typically recombinantly produced, has two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a nucleic acid encoding a fluorescent protein from one source and a nucleic acid encoding a peptide sequence from another source.
  • a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature.
  • the sequence In the context of a host cell, it means that the sequence encodes a protein which originates from a source different from the cell in which it is introduced or that the coding sequence comes from the same species as the cell in which it is introduced but it is considered heterologous due to its environment which is not natural, for example because it is under the control of a promoter which is not its natural promoter, or is introduced at a location which differs from its natural location.
  • the term «payload» refers to any nucleic acid sequence that can be transferred into a bacterium by a bacterial delivery vehicle.
  • the term «payload» may particularly refer to a plasmid, vector or cargo as defined hereafter.
  • the payload can be a phagemid or phasmid obtained from natural, evolved or engineered bacteriophage genome.
  • the payload can also be composed in part of phagemid or phasmid obtained from a natural, evolved or engineered bacteriophage genome.
  • the term “same payload” or “identical payload” are equivalent and refer to bacterial delivery vehicles containing payload with the same nucleic acid sequence enconding biological functions, i.e phage packaging, plasmid replication, plasmid selection, expression of proteins of interest in the target bacterium.
  • two payloads are considered as “same payload” when they have exactly the same nucleic acid sequence.
  • two payloads are considered as “same payload” when they encode the same biological functions.
  • the “same payload” may refer to two payloads having at least 70, 80, 90 or 95% of identity between each other.
  • the “same payload” may refer to two payloads having at least 70, 80, 90 or 95% of identity between each other and encoding the same biological functions.
  • the payloads have the same sequence except the tracer DNA sequences.
  • plasmid As used herein, the terms “plasmid”, “vector” and “cargo” are equivalent and refer to a payload, such as DNA or RNA, transferred into a host cell using a bacterial delivery vehicle.
  • a vector may comprise an origin of replication, a selectable marker, and optionally a suitable site for the insertion of a sequence or gene.
  • a vector can be either a self-replicating extrachromosomal vector or a vector which integrates into a host genome. It can also comprise expression elements including, for example, a promoter, the correct translation initiation sequence such as a ribosomal binding site and a start codon, a termination codon, and a transcription termination sequence.
  • a plasmid may also comprise other regulatory regions such as enhancers, silencers and boundary elements/insulators to direct the level of transcription of a given gene.
  • Vectors capable of directing the expression of genes and/or nucleic acid sequence to which they are operatively linked can also be referred to herein as “expression vectors”.
  • expression vectors There are several common types of vectors including plasmids, bacterial virus genomes, phagemids, virus genomes, cosmids, and artificial chromosomes.
  • the plasmid can be a vector for stable or transient expression of a gene or sequence.
  • the plasmid of the invention is a phagemid or plasmid and refers to a vector that derives from both a plasmid and a bacterial virus genome.
  • the plasmid may comprise a plasmid origin of replication (ori), a packaging signal and/or a tracer DNA sequence.
  • the term “packaged payload” or “payload packaged into a delivery vehicle” refers to a payload which is contained into a delivery vehicle to promote its delivery into the targeted bacteria.
  • the term “packaged plasmid” or “plasmid packaged into a bacterial virus particle” refers to a plasmid which is encapsidated into a proteinaceous envelope or capsid of a bacterial virus.
  • bacterial delivery vehicle refers to any mean that allows the transfer of a payload into a cell, preferably a bacterial cell.
  • delivery vehicle encompassed by the present invention including, without limitation, bacteriophage scaffold, virus scaffold, protein-based or peptide-based delivery vehicle. Any combination of delivery vehicles is also encompassed by the present invention.
  • the delivery vehicle can particularly refer to a bacteriophage derived scaffold and can be obtained from a natural, evolved or engineered capsid.
  • the bacterial delivery vehicle can also be a proteinaceous envelope or capsid.
  • the delivery vehicle is the payload as bacteria are naturally competent to take up a payload from the environment on their own.
  • the delivery system can be administered to a subject in need thereof.
  • the bacterial cell can be an isolated cell (e.g. in a bacteria cell culture) or a cell associated with a subject in which inhibiting or promoting the expression of a target gene or a sequence of interest is desired.
  • bacterial virus As used herein, the terms “bacterial virus”, “phage” or “bacteriophage” are used interchangeably and refer to a functional phage particle comprising a nucleic acid packaged into a proteinaceous envelope or capsid. The term also refers to portions of the bacterial virus, including, e.g., a head portion, or an assembly of phage components, which provide substantially the same functional activity.
  • bacterial virus particle or “virion” are equivalent and refer to a phage shape particle comprising a payload.
  • the bacterial virus particle can be a proteinaceous envelope or capsid. Particularly, it refers to a bacterial virus particle devoid of a bacteriophage genome.
  • proteinaceous envelope As used herein, the terms “proteinaceous envelope”, “capsid”, or “coat proteins” are equivalent and refer to the shape of the shell of proteins that protects the nucleic acid (i.e., genome) of a virus that is generally composed of structural units, or capsomers. Capsids are broadly classified according to their structure and shape known by the person skilled in the art. Preferably, they refer to bacteriophage capsids or coat proteins.
  • the terms “different bacterial delivery vehicle”, “different virus particles” or “distinct virus particles” or “different virus capsids” are equivalent and refer to the packaging of identical plasmids into bacterial delivery vehicles such as viral particles which are different, e.g. two different bacteriophage capsids.
  • the terms “packaged” or “encapsulated” are equivalent and refer to the packaging of a payload, especially a plasmid, into a bacterial delivery vehicle.
  • the term “packaging” may be equivalent to the term “encapsidation” which refers to the packaging of a payload into a bacterial virus particle or capsid.
  • orthogonal packaging sites refer to packaging signals that are different and independent, meaning that they lead to separate packaging, i.e. into at least two different bacterial delivery vehicles such as capsids or bacterial virus particles.
  • helper phage refers to a virus being co-infected with a principal defective virus, in particular the payload to be packaged into a bacterial virus particle.
  • the helper phage provides in trans the functions of which the first is deprived.
  • the packaged payload according to the invention may be produced using a helper phage strategy, well known to those skilled in the art.
  • the helper phage comprises all the genes coding for the structural and functional proteins that are indispensable for the payload according to the invention to be packaged or encapsidated (i.e. helper phage provides all the necessary gene products for particle formation).
  • helper phages are mutated wild-type phage containing a defective origin of replication or packaging signal, and hence, are inefficient in self-packaging, thus only bacterial virus particles carrying the deliverable nucleic acid (i.e., the payload or plasmid) will be produced.
  • Helper phages may be chosen so that they cannot induce lysis of the host used for the particle production. It is understood by one skilled in the art that some bacteriophages are defective and need a helper phage for replication and/or packaging. Thus, according to the bacterial virus chosen in the present invention to prepare the bacterial virus particles, one skilled in the art would know if and which a helper phage is required.
  • the terms “viral satellite genes” refers to genes derived from a satellite virus or satellite phage. Satellite phage are also known as a subviral agent and are composed of nucleic acid that depends on the co-infection of a host cell with a helper virus for all the morphogenetic functions, whereas for all its episomal functions (integration and immunity, multicopy plasmid replication) the satellite is completely autonomous from the helper.
  • the satellite genes can encode proteins that promote capsid size reduction of the helper phage, as described for the P4 Sid protein that controls the P2 capsid size to fit its smaller genome.
  • promoter and “transcriptional promoter” are equivalent and refer to a control region of a nucleic acid sequence at which transcription initiation and rate of transcription of the remainder of a nucleic acid sequence are controlled.
  • a promoter may also contain sub-regions to which regulatory proteins and molecules may bind, such as RNA polymerase and other transcription factors.
  • a promoter drives transcription of the nucleic acid sequence that it regulates.
  • a promoter is considered to be “operably linked” when it is in a correct functional location and orientation in relation to a nucleic acid sequence it regulates to control (“drive”) transcriptional initiation of that sequence.
  • the term “origin of replication” refers to a particular sequence in a genome at which replication is initiated. This can either involve the replication of DNA in living organisms such as prokaryotes and eukaryotes, or that of DNA or RNA in viruses. Preferably, it refers to a bacterial origin of replication or a phage origin of replication that is present on the plasmid according to the invention.
  • selection marker refers to a gene which is used to confirm the cloning of a gene or to confirm or ensure the presence of a plasmid in a bacterium.
  • the selection marker can be a marker gene providing selectable phenotypes such as drug resistance, auxotrophy, resistance to cytotoxic agents, or surface protein expression.
  • selectable phenotypes such as drug resistance, auxotrophy, resistance to cytotoxic agents, or surface protein expression.
  • an antibiotic-resistant gene, a gene allowing to overcome auxotrophy, a color-developing enzyme gene or a luminescent/fluorescent gene may be used. This confers a “selective advantage” to bacteria carrying such selection marker so as to be able to grow on medium supplied with antibiotics, heavy metals, or on medium without essential component such as amino acid.
  • the term “inactivation” refers to the direct or indirect inhibition or decrease of the expression of a gene, or of the biological function of the protein, or of the production of specific gene products (protein or RNA), compared to a normal or previous condition.
  • the regulation of the gene expression can be on the gene itself (i.e. cleavage, modifications), at the stage of transcription (i.e. using silencers or repressors), or using RNAi (e.g. siRNA, shRNA, endogenous microRNA or artificial microRNA), TALEN, ZFN, meganuclease or CRISPR/Cas system.
  • the CRISPR/Cas9 system is used to inactivate gene expression such as an antibiotic resistance gene, a virulence gene or a toxin gene present in the targeted bacteria.
  • bacteria refers to any prokaryotic microorganisms that exist as a single cell or in a cluster or aggregate of single cells.
  • the term “bacterium” encompasses all variants of bacteria (e.g., endogenous bacteria, which naturally reside in a closed system, environmental bacteria or bacteria released for bioremediation or other efforts).
  • Bacteria of the present disclosure include bacterial subdivisions of Eubacteria and Archaebacteria.
  • Eubacteria can be further subdivided into Gram-positive and Gram-negative Eubacteria. Also included herein are those classified based on gross morphology alone (e.g., cocci, bacilli).
  • the bacteria are Gram-negative cells, and in other embodiments, the bacteria are Gram-positive cells.
  • the terms “targeted bacteria” refers to the bacteria gender, species or strains that can be recognized by the bacterial delivery vehicle according to the invention and in which the bacterial delivery vehicle promote the introduction of the payload into said targeted bacteria.
  • the specific spectrum of bacteriophages is known by the person skilled in the art, so that the person skilled in the art would know what would be the targeted bacteria according to the chosen phage.
  • the targeted bacteria are bacteria present in the human body (i.e., bacteria of the microbiota). Even more preferably, the targeted bacteria are bacteria presenting specific phenotypical characteristics of interest, such as but not limited to antibiotic-resistance.
  • different bacteria can refer to distinct bacteria species or can also refer to different strains or genetic variants or subtypes or genotypes of bacteria.
  • the terms “containing the same payload” refers to the payload content of different bacterial delivery vehicles, meaning that identical payloads are packaged and contained into at least two different bacterial delivery vehicles.
  • the bacterial delivery vehicle is a bacterial virus
  • these terms mean that identical payloads are encapsidated and contained in at least two different bacterial virus capsids or particles (i.e., each bacteriophage has encapsidated and contains distinct copies of the same plasmid which present the same properties).
  • antibiotic and “antibacterial” are equivalent and refer to a type of antimicrobial active ingredient used in the treatment and prevention of bacterial infections. It can be a classical antibiotic that is produced by a microorganism that is antagonistic to the growth of other microorganisms and also encompasses more generally an antimicrobial agent that is capable of killing or inhibiting the growth of a microorganism, including chemically synthesized versions and variants of naturally occurring antibiotics.
  • antibiotic resistance gene encompasses a gene, or the encoding portion thereof, which encodes a product or transcribes a functional RNA that confers antibiotic resistance.
  • the antibiotic resistance gene may for example encode an enzyme which degrades an antibiotic, or an enzyme which modifies an antibiotic, or a pump such as an efflux pump, or a mutated target which suppresses the effect of the antibiotic.
  • antibiotic resistant bacteria refer to the ability of a bacterium to resist the effects of medication used against them.
  • treatment refers to any act intended to ameliorate the health status of patients or subjects such as therapy, prevention, prophylaxis and retardation of the infection. It designates both a curative treatment and/or a prophylactic treatment of a disease.
  • a curative treatment is defined as a treatment resulting in cure or a treatment alleviating, improving and/or eliminating, reducing and/or stabilizing the symptoms of a disease or the suffering that it causes directly or indirectly.
  • a prophylactic treatment comprises both a treatment resulting in the prevention of a disease and a treatment reducing and/or delaying the incidence of a disease or the risk of its occurrence.
  • such term refers to the improvement or eradication of a disease, a disorder, an infection or symptoms associated with it.
  • this term refers to minimizing the spread or the worsening of an infection; e.g., resulting from antibiotic-resistant bacteria.
  • disorder refers to an incorrectly functioning organ, part, structure, or system of the body.
  • the term disorder refers to a health disorder e.g. an illness that disrupts normal physical or mental functions. More preferably, the term disorder refers to a bacterial disease that is caused by or associated with bacteria or bacterial components that affect animals and/or humans. In a particular embodiment, the term disorder refers to the consequences of a bacterial infection, preferably by antibiotic resistant bacteria, or of a dysbiosis.
  • the term “disease” refers to a disordered or incorrectly functioning organ, part, structure, or system of the body resulting from the effect of genetic or developmental errors, infection, poisons, nutritional deficiency or imbalance, toxicity, or unfavorable environmental factors.
  • the term disease refers to a bacterial disease that is caused by bacteria or bacterial components that affect animals and/or humans.
  • the term disease refers to the consequences of a bacterial infection, preferably by antibiotic resistant bacteria, or of a dysbiosis.
  • a “pharmaceutical or veterinary composition” refers to a preparation of one or more of the active agents, such as the bacterial delivery vehicles containing the payload according to the invention, with optional other chemical components such as physiologically suitable carriers and excipients.
  • the purpose of a pharmaceutical or veterinary composition is to facilitate administration of the active agent to an organism.
  • Compositions of the present invention can be in a form suitable for any conventional route of administration or use.
  • the pharmaceutical or veterinary composition further comprises a pharmaceutically or veterinary acceptable vehicle.
  • a “pharmaceutically or veterinary acceptable vehicle” as referred to herein, is any known compound or combination of compounds that are known to those skilled in the art to be useful in formulating pharmaceutical or veterinary compositions.
  • the pharmaceutically or veterinary acceptable vehicle may be a solid, and the composition may be in the form of a powder or tablet.
  • the vehicle may also be an encapsulating material.
  • the vehicle is a finely divided solid that is in admixture with the finely divided active agents according to the invention.
  • the active agent e.g. the particle or system of the invention
  • the powders and tablets preferably contain up to 99% of the active agents.
  • the pharmaceutical or veterinary vehicle may be a gel and the composition may be in the form of a cream or the like. However, the pharmaceutical or veterinary vehicle may alternatively be a liquid, and the pharmaceutical or veterinary composition is in the form of a solution.
  • Liquid vehicles are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. Sterile liquid vehicles are useful in sterile liquid form compositions for enteral administration.
  • a “prebiotic” refers to an ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microbiota that may confer benefits upon the host.
  • a prebiotic can be a comestible food or beverage or ingredient thereof.
  • a prebiotic may be a selectively fermented ingredient.
  • Prebiotics may include complex carbohydrates, amino acids, peptides, minerals, or other essential nutritional components for the survival of the bacterial composition.
  • probiotic refers to a dietary supplement based on living microbes which, when taken in adequate quantitis, has a beneficial effect on the host organism by strengthening the intestinal ecosystem.
  • a probiotic can comprise a non-pathogenic bacterial or fungal population, e.g., an immunomodulatory bacterial population, such as an anti-inflammatory bacterial population, with or without one or more prebiotics. They contain a sufficiently high number of living and active probiotic microorganisms that can exert a balancing action on gut flora by direct colonisation.
  • probiotic is taken to mean any biologically active form of probiotic, preferably but not limited to lactobacilli, bifidobacteria, streptococci, enterococci, propionibacteria or saccaromycetes but even other microorganisms making up the normal gut flora, or also fragments of the bacterial wall or of the DNA of these microorganisms.
  • lactobacilli preferably but not limited to lactobacilli, bifidobacteria, streptococci, enterococci, propionibacteria or saccaromycetes but even other microorganisms making up the normal gut flora, or also fragments of the bacterial wall or of the DNA of these microorganisms.
  • a “therapeutically effective amount” is an amount which, when administered to a subject, is the amount of active agent that is needed to treat the targeted disease or disorder, or to produce the desired effect, e.g. result in effective delivery of the bacterial delivery vehicles containing the payload to the targeted bacteria.
  • the term “subject” or “patient” refers to an animal, preferably to a mammal, even more preferably to a human, including adult and child. However, the term “subject” also encompasses non-human animals, in particular mammals such as dogs, cats, horses, cows, pigs, sheep and non-human primates, among others.
  • percentage of identity in relation to sequences designates the level of identity or homology between said sequences and may be determined by techniques known per se in the art. Typically, the percentage of identity between two nucleic acid sequences is determined by means of computer programs such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1996, Genetics Computer Group, 575 Science Drive, Madison, Wis., USA 53711) (Needleman, S. B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453).
  • nucleic acid molecules may be aligned to each other using the Pileup alignment software available as part of the GCG program package.
  • the tool “Emboss needle” for pairwise sequence alignment of proteins providing by EMBL-EBI and available on: ebi.ac.uk using default settings: (I) Matrix: BLOSUM62, (ii) Gap open: 10, (iii) gap extend: 0.5, (iv) output format: pair, (v) end gap penalty: false, (vi) end gap open: 10, (vii) end gap extend: 0.5.
  • Sequence identity between nucleotide or amino acid sequences can be determined by comparing an alignment of the sequences. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position. Scoring an alignment as a percentage of identity is a function of the number of identical amino acids or bases at positions shared by the compared sequences. When comparing sequences, optimal alignments may require gaps to be introduced into one or more of the sequences to take into consideration possible insertions and deletions in the sequences. Sequence comparison methods may employ gap penalties so that, for the same number of identical molecules in sequences being compared, a sequence alignment with as few gaps as possible, reflecting higher relatedness between the two compared sequences, will achieve a higher score than one with many gaps. Calculation of maximum percent identity involves the production of an optimal alignment, taking into consideration gap penalties.
  • compatible size range or “size requirement” refers to the size (kilobase) of a payload as disclosed herein that will be differentially packaged into the at least two different bacterial delivery vehicles. It is known by the person skilled in the art that, for identical payloads to be packaged into different capsids, they need to be a suitable substrate for each packaging mechanisms (e.g. headful or cohesive packaging mechanisms) and meet the size requirement to fit in the cavity of either of the at least two different bacterial virus capsids.
  • packaging mechanisms e.g. headful or cohesive packaging mechanisms
  • PFU plaque forming unit
  • Lytic bacteria viruses lyse the host cell, causing a zone of clearing (or plaque) on a culture plate. Theoretically, each plaque is formed by one phage and the number of plaques multiplied by the dilution factor is equal to the total number of phages in a test preparation.
  • CFU colony forming unit, as it is well defined in the art. This unit is used to estimate the number of viable bacteria or yeast in a sample, and refers to a mass of bacterial cells or yeast cells from the same bacterial or yeast progenitor.
  • “In vitro” refers to procedures that are performed outside of a cell.
  • purified enzymes or extracts of cells can be used to perform procedures in a vessel, such as a test tube.
  • Example vivo refers to procedures that are performed outside of a multicellular organism, but use whole cells.
  • live cells from a subject such as a human
  • these cells can be used in testing procedures.
  • In vivo refers to procedures that are performed on a whole organism, such as a subject, including a human, such as in clinical trials. In vivo procedures can also be performed on non-human subjects, such as animal models.
  • a or “an” can refer to one of or a plurality of the elements it modifies (e.g., “a reagent” can mean one or more reagents) unless it is contextually clear either one of the elements or more than one of the elements is described.
  • “about 1, 2 and 3” refers to about 1, about 2 and about 3). Further, when a listing of values is described herein (e.g. about 50%, 60%, 70%, 80%, 85% or 86%) the listing includes all intermediate and fractional values thereof (e.g., 54%, 85.4%).
  • the present invention relates to a payload suitable to be packaged into at least two different bacterial delivery vehicles and comprising at least two orthogonal bacterial viruses packaging sites.
  • bacteria viruses need to package their genome inside their capsids.
  • Two major packaging mechanisms relying on two different types of termini can be used according to the present invention which permit payload packaging into at least two different bacterial delivery vehicles are described hereafter.
  • Two different packaging sites using the same mechanism and relying on different terminases can also be used according to the present invention.
  • the at least two packaging sites are not comprised between a pair of transposable ends of a transposable element, especially Tn5 mosaic ends.
  • the payload does not comprise any transposable end and/or transposable element.
  • the payload may also be the bacterial delivery vehicle as bacteria are naturally competent to take up a payload from the environment on their own.
  • a headful packing system may feed the nucleic acid into the cavity of a phage prohead in a linear processive manner causing the head to expand until it reaches a limit where the DNA inside exerts pressure against the inner wall sufficient to stop progression. This may induce a conformational change in the head, which activates endonucleolytic cleavage of incoming DNA opening the way for attachment of phage tails to make infectious particles.
  • Full heads may contain DNA molecules within a narrow size range. The capacity of the capsids may set a maximum size limitation on the packaged DNA.
  • Representative headful packaging systems include, but are not limited to, P1, P7, T4, KVP40, P22 and (1)29.
  • the packaging machinery may use a specific site to initiate and terminate packaging (cos). It may employ highly specific cos sites to initiate and terminate packaging. These sites are cut by terminase leaving base overhangs (cos L and cos R) at the ends of the packaged DNA. In ⁇ 's natural rolling circle packaging substrate, cos sites are spaced closer together than the full packaging limit determined by head size. As a result, cos site spacing, and not head capacity, normally determines the length of virion DNA.
  • the payload as disclosed hereafter can be packaged in the at least two different bacterial delivery vehicles by headful and/or cohesive packaging mechanisms.
  • the payload of the present invention is able to be packaged into at least two different bacterial delivery vehicles.
  • This payload comprises:
  • the size of the payload is selected so as to be suitable with the packaging into the considered bacterial delivery vehicles.
  • the considered bacterial delivery vehicles can be selected for being compatible, in particular having a size suitable with the payload to be packaged into such bacterial delivery vehicles.
  • the payload disclosed herein comprises a size range of at least 100 base pairs (bp), at least 1 kilobase (kb), at least 2 kilobases (kb), at least 3 kilobases (kb), at least 4 kb, at least 5 kb, at least 10 kb, at least 15 kb, at least 20 kb, at least 25 kb, at least 30 kb, at least 35 kb, at least 40 kb, at least 45 kb, at least 50 kb, at least 55 kb, at least 60 kb, at least 65 kb, at least 70 kb, at least 75 kb, at least 80 kb, at least 85 kb, at least 90 kb, at least 95 kb, at least 100 kb, at least 105 kb, at least 110 kb, at least 115 kb, at least 120 kb, at least 125 kb, at least 130 kb, at
  • the payload according to the invention comprises at least two different packaging signal sequences.
  • it should to be a suitable substrate for each packaging mechanisms (i.e. headful or cohesive packaging mechanisms). This includes size requirement, no inhibition between packaging sites, and origin of replication compatible with both packaging systems.
  • Packaging sites include but are not limited to SPP1 (SPP1 pac site), P1 (P1 pac site), T1 (T1 pac site), T7 (T7 concatemer junction), lambda ( ⁇ cos site), P4 (P4 cos site), mu (mu pac site), P22 (P22 pac site), ⁇ 8 ( ⁇ 8 pac site), Sf6 (Sf6 pac site), 149 (149 pac site), and A1 122 (A1 122-concatamer junction).
  • packaging sites include HK97 packaging site, mEp235 packaging site, mEp043 packaging site, mEp234 packaging site, mEp505 packaging site, mEp506 packaging site, mEpX1 packaging site, mEpX2 packaging site, mEp390 packaging site, mEp460 packaging site, mEp213 packaging site, mEp237 packaging site, HK022 packaging site and phi80 packaging site.
  • the packaging site is termed the pac site.
  • the packaging site is referred to as a concatemer junction (e.g. T7 concatemer junction).
  • the packaging site is substantially isolated from sequences naturally occurring adjacent thereto in the bacteria virus genome.
  • the packaging site may be unknown.
  • pac sites can be determined by taking advantage of the property that plasmids containing a functional bacterial virus pac site are packaged.
  • the DNA sequences necessary for packaging by bacterial virus ⁇ were determined by incorporating small restriction fragments of the) ⁇ , phage genomic DNA into a plasmid (Hohn, B 1983 PNAS USA 80:7456-7460).
  • ⁇ (Miwa, T 1982 Gene 20:267-279); Mu (Groenen, MA and van de Putte, P 1985 Virology 144:520-522); filamentous bacteria viruses including fl, fd, M13, and Ike (Russel, M and Model, P 1989 J Virol 1989 63:3284-3295); P22 (Petri, J B and Schmieger, H 1990 Gene 88:47-55; Wu, H et al.
  • the payload according to the invention comprises at least two orthogonal packaging sites, preferably two orthogonal bacterial virus packaging sites, that allow packaging of the payload into at least two different bacterial delivery vehicles selected in the group consisting of pac sites, cos sites and concatemer junction sites or any other packaging sites with a different or unknown packaging mechanism or any combination thereof.
  • the at least two different packaging sites can be at least two different cos sites (for example ⁇ and P4 cos sites), at least two different pac sites (for example Mu, P1 and P22 pac sites) or at least two different concatemer junction sites (for example T7 and AI 122 concatemer junctions).
  • cos sites for example ⁇ and P4 cos sites
  • pac sites for example Mu, P1 and P22 pac sites
  • concatemer junction sites for example T7 and AI 122 concatemer junctions
  • the at least two different packaging sites can be at least one cos site and at least one pac site (for example ⁇ cos site and P22 pac site), at least one cos site and at least one concatemer junction site (for example ⁇ cos site and T7 concatemer junction), at least one pac site and at least one concatemer junction site (for example P22 pac site and T7 concatemer junction), or at least one cos site, at least one pac site and at least one concatemer junction site (for example ⁇ cos site, P22 pac site and T7 concatemer junction).
  • the payload according to the invention comprises at least two different packaging sites which can be selected in the group consisting of ⁇ cos site, P4 cos site, SPP1 pac site, P1 pac site, T1 pac site, mu pac site, P22 pac site, ⁇ 8 pac site, Sf6 pac site, 149 pac site, T7 concatemer junction, A1 122-concatemer junction.
  • the payload according to the invention comprises at least two different packaging sites which are ⁇ cos site and P4 cos site.
  • the payload according to the invention comprises ⁇ cos site and P4 cos site, or ⁇ cos site, P4 cos site and P1 pac site, or ⁇ cos site, P4 cos site and T7 concatemer junction, or ⁇ cos site, P4 cos site, P1 pac site and T7 concatemer junction.
  • the payload according to the invention comprises at least two different packaging sites which are selected in the table 1 below.
  • the at least two different packaging sites are selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 and any combination thereof.
  • the payload according to the invention comprises a packaging site of SEQ ID No. 3 and at least one different packaging site selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6.
  • the payload according to the invention comprises at least three different packaging sites.
  • the at least three packaging sites are selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6.
  • the payload according to the invention comprises three packaging sites of SEQ ID No. 1, SEQ ID No. 3 and SEQ. ID No. 5, respectively.
  • the at least two or at least three different packaging sites have at least 70% sequence identity, at least 75% sequence identity, at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 95% sequence identity with any of the of the SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6.
  • packaging sites having less than 80% of sequence identity between each other's, less than 75% of sequence identity, less than 70% of sequence identity, less than 65% of sequence identity, less than 60% of sequence identity, less than 55% of sequence identity, less than 50% of sequence identity, less than 45% of sequence identity, less than 40% of sequence identity, less than 35% of sequence identity, less than 30% of sequence identity, less than 25% of sequence identity, less than 20% of sequence identity, less than 15% of sequence identity, or less than 10% of sequence identity.
  • the present invention envisions the use of origins of replication known in the art that have been identified from species-specific plasmid DNAs (e.g. CoIE1, R1, pT181, pC194, pE194, RSF1010, pSC101, pMB1, R6K, RK2, p15a, pBBR1, pUC, pBR322 and the like), from bacterial virus (e.g. ⁇ X174, M13, F1 and P4) and from bacterial chromosomal origins of replication (e.g. oriC).
  • species-specific plasmid DNAs e.g. CoIE1, R1, pT181, pC194, pE194, RSF1010, pSC101, pMB1, R6K, RK2, p15a, pBBR1, pUC, pBR322 and the like
  • bacterial virus e.g. ⁇ X174, M13, F1 and P4
  • oriC bacterial chromoso
  • Plasmid replication depends on host enzymes and on plasmid-controlled cis and trans determinants. For example, some plasmids have determinants that are recognized in almost all gram-negative bacteria and act correctly in each host during replication initiation and regulation. Other plasmids possess this ability only in some bacteria (Kues, U and Stahl, U 1989 Microbiol Rev 53:491-516).
  • Plasmids are replicated by three general mechanisms, namely theta type, strand displacement, and rolling circle (reviewed by Del Solar et al. 1998 Microbio and Molec Biol. Rev 62:434-464) that start at the origin of replication.
  • This replication origins contain sites that are required for interactions of plasmid and/or host encoded proteins.
  • Origins of replication used on the payload of the invention may be moderate copy number, such as colE1 ori from pBR322 (15-20 copies per cell) or the R6K plasmid (15-20 copies per cell) or may be high copy number, e.g. pUC oris (500-700 copies per cell), pGEM oris (300-400 copies per cell), pTZ oris (>1000 copies per cell) or pBluescript oris (300-500 copies per cell).
  • pUC oris 500-700 copies per cell
  • pGEM oris 300-400 copies per cell
  • pTZ oris >1000 copies per cell
  • pBluescript oris 300-500 copies per cell.
  • the bacterial origin of replication is selected in the group consisting of ColE1, pMB1 and variants (pBR322, pET, pUC, etc.), p15a, ColA, ColE2, pOSAK, pSC101, R6K, IncW (pSa etc.), IncFII, pT181, P1, F IncP, IncC, IncJ, IncN, IncP1, IncP4, IncQ, IncH11, RSF1010, CloDF13, NTP16, R1, f5, pPS10, pC194, pE194, BBR1, pBC1, pEP2, pWVO1, pLF1311, pAP1, pWKS1, pLS1, pLS11, pUB6060, pJD4, pIJ101, pSN22, pAMbeta1, pIP501, pIP407, ZM6100(Sa), pCU1, RA3, pMOL98, RK2/RP4/RP
  • the bacterial origin of replication is a E. coli origin of replication selected in the group consisting of ColE1, pMB1 and variants (pBR322, pET, pUC, etc.), p15a, ColA, ColE2, pOSAK, pSC101, R6K, IncW (pSa etc.), IncFII, pT181, P1, F IncP, IncC, IncJ, IncN, IncP1, IncP4, IncQ, IncH11, RSF1010, CloDF13, NTP16, R1, f5, pPS10.
  • E. coli origin of replication selected in the group consisting of ColE1, pMB1 and variants (pBR322, pET, pUC, etc.), p15a, ColA, ColE2, pOSAK, pSC101, R6K, IncW (pSa etc.), IncFII, pT181, P1, F IncP, IncC, IncJ, IncN, IncP1, IncP4, IncQ, IncH11
  • the bacterial origin of replication is selected in the group consisting of pC194, pE194, BBR1, pBC1, pEP2, pWVO1, pLF1311, pAP1, pWKS1, pLS1, pLS11, pUB6060, pJD4, 0.1101, pSN22, pAMbeta1, pIP501, pIP407, ZM6100(Sa), pCU1, RA3, pMOL98, RK2/RP4/RP1/R68, pB10, R300B, pRO1614, pRO1600, pECB2, pCM1, pFA3, RepFIA, RepFIB, RepFIC, pYVE439-80, R387, phasyl, RA1, TF-FC2, pMV158 and pUB113.
  • the bacterial origin of replication is ColE1.
  • the payload according to the invention may comprise a phage replication origin which can initiate, with complementation of a complete phage genome, the replication of the payload for later encapsulation into the different bacterial delivery vehicles.
  • a phage origin of replication comprised in the payload of the invention can be any origin of replication found in a phage.
  • the phage origin of replication can be the wild-type or non-wildtype sequence of the M13, f1, ⁇ X174, P4, Lambda, P2, Lambda-like, HK022, mEP237, HK97, HK629, HK630, mEP043, mEP213, mEP234, mEP390, mEP460, mEPx1, mEPx2, phi80, mEP234, T2, T4, T5, T7, RB49, phiX174, R17, PRD1 P1-like, P2-like, P22, P22-like, N15 and N15-like bacteriophages.
  • the phage origin of replication is selected in the group consisting of phage origins of replication of M13, f1, ⁇ X174, P4, and Lambda.
  • the phage origin of replication is the P4 origin of replication.
  • a promoter may be classified as strong or weak according to its affinity for RNA polymerase.
  • the strength of a promoter may depend on whether initiation of transcription occurs at that promoter with high or low frequency. Different promoters with different strengths may be used in the present invention leading to different levels of gene/protein expression (e.g. the level of expression initiated from an mRNA originating from a weak promoter is lower than the level of expression initiated from a strong promoter).
  • a promoter sequence may be selected from a large number of known bacterial genes expressed by various bacterial species. Also, method of prokaryotic promoter prediction exists, and can be based on DNA stability analysis as described in Kanhere and Bansal (BMC Bioinformatics 2005, 6:1). The choice of promoter on the payload according to the present invention can thus be made based on the bacteria to target.
  • a nucleic acid sequence of interest may be positioned under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with the nucleic acid sequence of interest in its natural environment.
  • Examples of bacterial promoters for use in accordance with the present invention include, without limitation, positively regulated E. coli promoters such as positively regulated ⁇ 70 promoters (e.g., inducible pBad/araC promoter, Lux cassette right promoter, modified lambda Prm promote, plac Or2-62 (positive), pBad/AraC with extra REN sites, pBad, P(Las) TetO, P(Las) CIO, P(Rh1), Pu, FecA, pRE, cadC, hns, pLas, pLux), a “s” promoter (e.g., Pdps), ⁇ 32 promoters (e.g., heat shock) and ⁇ 54 promoters (e.g., glnAp2); negatively regulated E.
  • positively regulated E. coli promoters such as positively regulated ⁇ 70 promoters (e.g., inducible pBad/
  • coli promoters such as negatively regulated ⁇ 70 promoters (e.g., Promoter (PRM+), modified lambda Prm promoter, TetR-TetR-4C P(Las) TetO, P(Las) CIO, P(Lac) IQ, RecA_DlexO_DLac01, dapAp, FecA, Pspac-hy, pel, plux-cl, plux-lac, CinR, CinL, glucose controlled, modified Pr, modifed Prm+, FecA, Pcya, rec A (SOS), Rec A (SOS), EmrR_regulated, Betl_regulated, pLac_lux, pTet_Lac, pLac/Mnt, pTet/Mnt, LsrA/cI, pLux/cI, Lad, LacIQ, pLacIQ1, pLas/cI, pLas/Lux, pLux/Las
  • subtilis promoters such as repressible B. subtilis ⁇ A promoters (e.g., Gram-positive IPTG-inducible, Xyl, hyper-spank), ⁇ promoters, and the BioFAB promoters disclosed in Mutalik VK et al (Nature Methods, 2013, 10: 354-360, see in particular the supplementary data) as well as on the BioFAB website (biofab.synberc.org).
  • Other inducible microbial promoters and/or bacterial promoters may be used in accordance with the present invention.
  • An inducible promoter for use in accordance with the present disclosure may be induced by (or repressed by) one or more physiological condition(s), such as changes in pH, temperature, radiation, osmotic pressure, saline gradients, cell surface binding, and the concentration of one or more extrinsic or intrinsic inducing agent(s).
  • the extrinsic inducer or inducing agent may comprise, without limitation, amino acids and amino acid analogs, saccharides and polysaccharides, nucleic acids, protein transcriptional activators and repressors, cytokines, toxins, petroleum-based compounds, metal containing compounds, salts, ions, enzyme substrate analogs, hormones or combinations thereof.
  • Particularly preferred bacterial promoters for use in accordance with the present invention may be selected from constitutive promoters regulated by ⁇ 70 such as the promoters of the Anderson collection (parts.igem.org): BBa_J23100, BBa_J23101, BBa_J23102, BBa_J23103, BBa_J23104, BBa_J23105, BBa_J23106, BBa_J23107, BBa_J23108, BBa_J23109, BBa_J23110, BBa_J23111, BBa_J23112, BBa_J23113, BBa_J23114, BBa_J23115, BBa_J23116, BBa_J23117, BBa_J23118, and BBa_J23119.
  • ⁇ 70 such as the promoters of the Anderson collection (parts.igem.org): BBa_J23100, BBa_J23101,
  • a promoter may or may not be used in conjunction with an “enhancer,” which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence downstream of the promoter.
  • the enhancer may be located at any functional location before or after the promoter.
  • the payload may comprise a terminator sequence, or terminator.
  • a “terminator,” as used herein, is a nucleic acid sequence that causes transcription to stop.
  • a terminator may be unidirectional or bidirectional. It is comprised of a DNA sequence involved in specific termination of an RNA transcript by an RNA polymerase.
  • a terminator sequence prevents transcriptional activation of downstream nucleic acid sequences by upstream promoters.
  • a terminator that ends the production of an RNA transcript is contemplated.
  • a terminator may be necessary in vivo to achieve desirable gene/protein expression levels.
  • terminator The most commonly used type of terminator is a forward terminator. When placed downstream of a nucleic acid sequence of interest that is usually transcribed, a forward transcriptional terminator will cause transcription to abort.
  • bidirectional transcriptional terminators are provided, which usually cause transcription to terminate on both the forward and reverse strand.
  • reverse transcriptional terminators are provided, which usually terminate transcription on the reverse strand only.
  • terminators usually fall into two categories (1) rho-independent terminators and (2) rho-dependent terminators.
  • Rho-independent terminators are generally composed of palindromic sequence that forms a stem loop rich in G-C base pairs followed by a string of uracil bases.
  • Terminators for use in accordance with the present invention include any terminator of transcription described herein or known to one of ordinary skill in the art.
  • Examples of terminators include, without limitation, the termination sequences of genes such as, for example, the bovine growth hormone terminator, and viral termination sequences such as, for example, the TO terminator, the TE terminator, Lambda T1 and the T1T2 terminator found in bacterial systems.
  • the termination signal may be a sequence that cannot be transcribed or translated, such as those resulting from a sequence truncation.
  • Terminators for use in accordance with the present invention also include terminators disclosed in Chen Y J et al (2013, Nature Methods, 10: 659-664), and the BioFAB terminators disclosed in Cambray G et al (Nucl Acids Res, 2013, 41(9): 5139-5148).
  • the payload comprises a sequence of interest under the control of a promoter.
  • the sequence of interest is a programmable nuclease circuits to be delivered to the targeted bacteria.
  • This programmable nuclease circuit may be able to mediate in vivo sequence-specific elimination of bacteria that contain a target gene of interest (e.g. a gene that is harmful to humans).
  • Some embodiments of the present disclosure relate to engineered variants of the Type II CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated) system of Streptococcus pyogenes .
  • programmable nucleases that can be used include other CRISPR-Cas systems, engineered TALEN (Transcription Activator-Like Effector Nuclease) variants, engineered zinc finger nuclease (ZFN) variants, natural, evolved or engineered meganuclease or recombinase variants, and any combination or hybrids of programmable nucleases.
  • the engineered autonomously distributed circuits provided herein may be used to selectively cleave DNA encoding a gene of interest such as, for example, a toxin gene, a virulence factor gene, an antibiotic resistance gene, a remodeling gene or a modulatory gene (cf. WO2014124226 and US2015/0064138).
  • sequences of interest can be added to the payload so as to be delivered to targeted bacteria.
  • the sequence of interest added to the payload leads to cell death of the targeted bacteria.
  • the nucleic acid sequence of interest added to the payload may encode holins or toxins.
  • sequence of interest circuit added to the payload does not lead to bacteria death.
  • the sequence of interest may encode reporter genes leading to a luminescence or fluorescence signal, or being able to elicit an immune response.
  • the sequence of interest may comprise proteins and enzymes achieving a useful function such as modifying the metabolism of the bacteria or the composition of its environment and/or such as producing a therapeutic effect.
  • the nucleic sequence of interest is selected in the group consisting of a Cas nuclease, a Cas9 nuclease, a guide RNA, a single guide RNA (sgRNA), a CRISPR locus, a gene expressing an enzyme such as a nuclease or a kinase, a TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a membrane protein, a structural protein, a secreted protein, resistance to an antibiotic or to a drug in general, a gene expressing a toxic protein or a toxic factor and a gene expressing a virulence protein or a virulence factor or any combination thereof.
  • the payload according to the invention comprises a sequence of interest that encodes a bacteriocin, which can be a proteinaceous toxin produced by bacteria to kill or inhibit growth of other bacteria.
  • Bacteriocins are categorized in several ways, including producing strain, common resistance mechanisms, and mechanism of killing. Such bacteriocin had been described from gram negative bacteria (e.g. microcins, colicin-like bacteriocins and tailocins) and from gram positive bacteria (e.g. Class I, Class II, Class III or Class IV bacteriocins).
  • the payload according to the invention further comprises a sequence of interest encoding a toxin selected in the group consisting of microcins, colicin-like bacteriocins, tailocins, Class I, Class II, Class III and Class IV bacteriocins.
  • the corresponding immunity polypeptide i.e. anti-toxin
  • the corresponding immunity polypeptide may be used to protect bacterial cells (see review by Cotter et al., Nature Reviews Microbiology 11: 95, 2013, which is hereby incorporated by reference in its entirety) for payload production and packaging purpose but is absent in the pharmaceutical composition and in the targeted bacteria in which the payload of the invention is delivered.
  • the CRISPR system contains two distinct elements, i.e. i) an endonuclease, in this case the CRISPR associated nuclease (Cas or “CRISPR associated protein”) and ii) a guide RNA.
  • the guide RNA is in the form of a chimeric RNA which consists of the combination of a CRISPR (RNAcr) bacterial RNA and a RNAtracr (trans-activating RNA CRISPR) (Jinek et al., Science 2012).
  • the gRNA combines the targeting specificity of the cRNA corresponding to the “spacing sequences” that serve as guides to the Cas proteins, and the conformational properties of the Rtracr in a single transcript.
  • the target genomic sequence can be permanently modified or interrupted. The modification is advantageously guided by a repair matrix.
  • the CRISPR system includes two main classes depending on the nuclease mechanism of action:
  • the sequence of interest according to the present invention comprises a nucleic acid sequence encoding Cas protein.
  • CRISPR enzymes are available for use as a sequence of interest on the payload according to the present invention.
  • the CRISPR enzyme is a Type II CRISPR enzyme.
  • the CRISPR enzyme catalyzes DNA cleavage.
  • the CRISPR enzyme catalyzes RNA cleavage.
  • the CRISPR enzymes may be coupled to a sgRNA.
  • the sgRNA targets a gene selected in the group consisting of an antibiotic resistance gene, virulence protein or factor gene, toxin protein or factor gene, a bacterial receptor gene, a membrane protein gene, a structural protein gene, a secreted protein gene and a gene expressing resistance to a drug in general.
  • Non-limiting examples of Cas proteins as part of a multi-subunit effector or as a single-unit effector include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Cas11 (SS), Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), C2c4, C2c8, C2c5, C2c10, C2c9, Cas13a (C2c2), Cas13b (C2c6), Cas13c (C2c7), Cas13d, Csa5, Csc1, Csc2, Cse1, Cse2, Csy1, Csy2, Csy3, Csf1, Csf2, Csf3, Csf4, Csm2, Csm3, Csm4, C
  • the CRISPR enzyme is any Cas9 protein, for instance any naturally-occurring bacterial Cas9 as well as any variants, homologs or orthologues thereof.
  • Cas9 is meant a protein Cas9 (also called Csnl or Csx12) or a functional protein, peptide or polypeptide fragment thereof, i.e. capable of interacting with the guide RNA(s) and of exerting the enzymatic activity (nuclease) which allows it to perform the double-strand cleavage of the DNA of the target genome.
  • Cas9 can thus denote a modified protein, for example truncated to remove domains of the protein that are not essential for the predefined functions of the protein, in particular the domains that are not necessary for interaction with the gRNA (s).
  • Cas9 the entire protein or a fragment thereof
  • the sequence encoding Cas9 can be obtained from any known Cas9 protein (Fonfara et al., 2014; Koonin et al., 2017).
  • Cas9 proteins useful in the present invention include, but are not limited to, Cas9 proteins of Streptococcus pyogenes (SpCas9), Streptococcus thermophiles (St1Cas9, St3Cas9), Streptococcus mutans, Staphylococcus aureus (SaCas9), Campylobacter jejuni (CjCas9), Francisella novicida (FnCas9) and Neisseria meningitides (NmCas9).
  • SpCas9 Streptococcus pyogenes
  • St1Cas9, St3Cas9 Streptococcus thermophiles
  • Streptococcus mutans
  • Cpf1 (Cas12a) (the entire protein or a fragment thereof) as used in the context of the invention can be obtained from any known Cpf1 (Cas12a) protein (Koonin et al., 2017).
  • Cpf1 (Cas12a) proteins useful in the present invention include, but are not limited to, Cpf1(Cas12a) proteins of Acidaminococcus sp, Lachnospiraceae bacteriu and Francisella novicida.
  • Cas13a (the entire protein or a fragment thereof) as used in the context of the invention can be obtained from any known Cas13a (C2c2) protein (Abudayyeh et al., 2017).
  • Cas13a (C2c2) proteins useful in the present invention include, but are not limited to, Cas13a (C2c2) proteins of Leptotrichia wadei (LwaCas13a).
  • Cas13d (the entire protein or a fragment thereof) as used in the context of the invention can be obtained from any known Cas13d protein (Yan et al., 2018).
  • Cas13d proteins useful in the present invention include, but are not limited to, Cas13d proteins of Eubacterium siraeum and Ruminococcus sp.
  • the nucleic sequence of interest is a CRISPR/Cas9 system for the reduction of gene expression or inactivation a gene selected in the group consisting of an antibiotic resistance gene, virulence factor or protein gene, toxin factor or protein gene, a gene expressing a bacterial receptor, a membrane protein, a structural protein, a secreted protein, and a gene expressing resistance to a drug in general.
  • the CRISPR system is used to target and inactivate a virulence factor.
  • a virulence factor can be any substance produced by a pathogen that alter host-pathogen interaction by increasing the degree of damage done to the host.
  • Virulence factors are used by pathogens in many ways, including, for example, in cell adhesion or colonization of a niche in the host, to evade the host's immune response, to facilitate entry to and egress from host cells, to obtain nutrition from the host, or to inhibit other physiological processes in the host.
  • Virulence factors can include enzymes, endotoxins, adhesion factors, motility factors, factors involved in complement evasion, and factors that promote biofilm formation.
  • such targeted virulence factor gene can be E.
  • coli virulence factor gene such as, without limitation, EHEC-H1yA, Stx1 (VT1), Stx2 (VT2), Stx2a (VT2a), Stx2b (VT2b), Stx2c (VT2c), Stx2d (VT2d), Stx2e (VT2e) and Stx2f (VT2f), Stx2h (VT2h), fimA, fimF, fimH, neuC, kpsE, sfa, foc, iroN, aer, iha, papC, papGI, papGII, papGIII, h1yC, cnf1, hra, sat, ireA, usp ompT, ibeA, malX, fyuA, irp2, traT, afaD, ipaH, eltB, estA, bfpA, eaeA, espA, aa
  • such targeted virulence factor gene can be Shigella dysenteriae virulence factor gene such as, without limitation, stx1 and stx2.
  • such targeted virulence factor gene can be Yersinia pestis virulence factor gene such as, without limitation, yscF (plasmid-borne (pCD1) T3SS external needle subunit).
  • yscF plasmid-borne (pCD1) T3SS external needle subunit
  • such targeted virulence factor gene can be Francisella tularensis virulence factor gene such as, without limitation, fs1A.
  • such targeted virulence factor gene can be Bacillus anthracia virulence factor gene such as, without limitation, pag (Anthrax toxin, cell-binding protective antigen).
  • such targeted virulence factor gene can be Vibrio cholera virulence factor gene such as, without limitation, ctxA and ctxB (cholera toxin), tcpA (toxin co-regulated pilus), and toxT (master virulence regulator).
  • Vibrio cholera virulence factor gene such as, without limitation, ctxA and ctxB (cholera toxin), tcpA (toxin co-regulated pilus), and toxT (master virulence regulator).
  • such targeted virulence factor gene can be Pseudomonas aeruginosa virulence factor genes such as, without limitation, pyoverdine (e.g., sigma factor pvdS, biosynthetic genes pvdL, pvdl, pvdJ, pvdH, pvdA, pvdF, pvdQ, pvdN, pvdM, pvdO, pvdP, transporter genes pvdE, pvdR, pvdT, opmQ), siderophore pyochelin (e.g., pchD, pchC, pchB, pchA, pchE, pchF and pchG, and toxins (e.g., exoU, exoS and exoT).
  • pyoverdine e.g., sigma factor pvdS, bio
  • such targeted virulence factor gene can be Klebsiella pneumoniae virulence factor genes such as, without limitation, fimA (adherence, type I fimbriae major subunit), and cps (capsular polysaccharide).
  • Klebsiella pneumoniae virulence factor genes such as, without limitation, fimA (adherence, type I fimbriae major subunit), and cps (capsular polysaccharide).
  • such targeted virulence factor gene can be Acinetobacter baumannii virulence factor genes such as, without limitation, ptk (capsule polymerization) and epsA (assembly).
  • such targeted virulence factor gene can be Salmonella enterica Typhi virulence factor genes such as, without limitation, MIA (invasion, SPI-1 regulator), ssrB (SPI-2 regulator), and those associated with bile tolerance, including efflux pump genes acrA, acrB and to 1C.
  • such targeted virulence factor gene can be Fusobacterium nucleatum virulence factor genes such as, without limitation, FadA and TIGIT.
  • such targeted virulence factor gene can be Bacteroides fragilis virulence factor genes such as, without limitation, bft.
  • the CRISPR/Cas9 system is used to target and inactivate an antibiotic resistance gene such as, without limitation, GyrB, ParE, ParY, AAC(1), AAC(2′), AAC(3), AAC(6′), ANT(2′′), ANT(3′′), ANT(4′), ANT(6), ANT(9), APH(2′′), APH(3′′), APH(3′), APH(4), APH(6), APH(7′′), APH(9), ArmA, RmtA, RmtB, RmtC, Sgm, AER, BLA1, CTX-M, KPC, SHV, TEM, BlaB, CcrA, IMP, NDM, VIM, ACT, AmpC, CMY, LAT, PDC, OXA ⁇ -lactamase, mecA, Omp36, OmpF, PIB, bla (blal, blaR1) and mec (mecl, mecR1) operons,
  • the CRISPR/Cas9 system is used to target and inactivate a bacterial toxin gene.
  • Bacterial toxin can be classified as either exotoxins or endotoxins. Exotoxins are generated and actively secreted; endotoxins remain part of the bacteria. The response to a bacterial toxin can involve severe inflammation and can lead to sepsis.
  • Such toxin can be for example Botulinum neurotoxin, Tetanus toxin, Staphylococcus toxins, Diphtheria toxin, Anthrax toxin, Alpha toxin, Pertussis toxin, Shiga toxin, Heat-stable enterotoxin ( E. coli ST), colibactin, BFT ( B. fragilis toxin) or any toxin described in Henkel et al., (Toxins from Bacteria in EXS. 2010; 100: 1-29).
  • the payload according to the invention may further comprise a selection marker.
  • the selection marker provides a selective advantage to the bacterial cell infected by the payload, such as resistance to antibiotics, resistance to heavy metals, complementing a host auxotrophy and/or exhibiting fluorescent or luminescent proteins.
  • the inclusion of the suitable selectable marker gene in a payload allows testing and/or detection for successful delivery of the payload according to the invention.
  • the payload according to the invention may comprise one or more nucleic acid sequences encoding selectable marker such as auxotrophic markers (e.g., LEU2, URA3, TRP 1, HIS3, DapA or ThyA) (Peubez et al, 2010), detectable labels such as fluorescent or luminescent proteins (e.g., GFP, eGFP, DsRed, CFP, YFP), or protein conferring resistance to a chemical/toxic compound (e.g., MGMT gene conferring resistance to temozolomide, kanamycin resistance, chloramphenicol resistance, etc.) or any combinations thereof.
  • selectable marker such as auxotrophic markers (e.g., LEU2, URA3, TRP 1, HIS3, DapA or ThyA) (Peubez et al, 2010), detectable labels such as fluorescent or lumin
  • an antibiotic resistance gene is a commonly used selection marker to facilitate molecular biology cloning of the payload and to allow the detection or selection of bacteria transformed by such payload.
  • Antibiotic resistance genes are well known in the art and include but are not limited to ampicillin resistance (Amp), chloramphenicol resistance (Cm), tetracycline resistance (Tet), kanamycin resistance (Kan), hygromycin resistance (Qiyg or hph genes), and zeomycin resistance (Zeo).
  • antibiotic-free selection systems include bacterial toxin-antitoxin systems [Engelberg-Kulka, H. and Glaser, G., Annu. Rev. Microbiol. 53 (1999) 43-70] and genes responsible for resistance against heavy metals, such as tellurium [Silver, S, and Phung, L. T., Annu. Rev. Microbiol. 50 (1996) 753-789], and systems, in which the payload encodes a gene complementing a host auxotrophy [Wang, M. D., et al., J. Bacteriol. 169 (1987) 5610-5614].
  • the payload according to the invention comprises an auxotrophic marker.
  • the bacteria targeted by bacterial delivery vehicles can be any bacteria present in a mammal organism. It can be any commensal, symbiotic or pathogenic bacteria of the microbiota or microbiome.
  • a microbiome may comprise of a variety of endogenous bacterial species, any of which may be targeted in accordance with the present disclosure.
  • the genus and/or species of targeted endogenous bacterial cells may depend on the type of bacteriophages being used for preparing the bacterial virus particles. For example, some bacteriophages exhibit tropism for, or preferentially target, specific host species of bacteria. Other bacteriophages do not exhibit such tropism and may be used to target a number of different genus and/or species of endogenous bacterial cells.
  • bacterial cells include, without limitation, cells from bacteria of the genus Yersinia, Escherichia, Klebsiella, Acinetobacter, Bordetella, Neisseria, Aeromonas, Franciesella, Corynebacterium, Citrobacter, Chlamydia, Hemophilus, Brucella, Mycobacterium, Legionella, Rhodococcus, Pseudomonas, Helicobacter, Vibrio, Bacillus, Erysipelothrix, Salmonella, Streptomyces, Streptococcus, Staphylococcus, Bacteroides, Prevotella, Clostridium, Bifidobacterium, Clostridium, Brevibacterium, Lactococcus, Leuconostoc, Actinobacillus, Selnomonas, Shigella, Zymonas, Mycoplasma, Treponema, Leuconostoc, Corynebacterium, Enterococc
  • delivery vehicles may target (e.g., specifically target) a bacterial cell from any one or more of the foregoing genus of bacteria to specifically deliver the payload according to the invention.
  • the targeted bacteria can be selected from the group consisting of Yersinia spp., Escherichia spp., Klebsiella spp., Acinetobacter spp., Pseudomonas spp., Helicobacter spp., Vibrio spp., Salmonella spp., Streptococcus spp., Staphylococcus spp., Bacteroides spp., Clostridium spp., Shigella spp., Enterococcus spp., Enterobacter spp., Listeria spp., Cutibacterium spp., Propionibacterium spp., Fusobacterium spp., Porphyromonas spp. and Gardnerella spp.
  • bacterial cells of the present invention are anaerobic bacterial cells (e.g., cells that do not require oxygen for growth).
  • Anaerobic bacterial cells include facultative anaerobic cells such as but not limited to Escherichia coli, Shewanella oneidensis, Gardnerella vaginalis and Listeria .
  • Anaerobic bacterial cells also include obligate anaerobic cells such as, for example, Bacteroides, Clostridium, Cutibacterium, Propionibacterium, Fusobacterium and Porphyromonas species.
  • anaerobic bacteria are most commonly found in the gastrointestinal tract.
  • the targeted bacteria are thus bacteria most commonly found in the gastrointestinal tract.
  • Bacteriophages used for preparing the bacterial virus particles, and then the bacterial virus particles may target (e.g., to specifically target) anaerobic bacterial cells according to their specific spectra known by the person skilled in the art to specifically deliver the payload.
  • the targeted bacterial cells are, without limitation, Bacteroides thetaiotaomicron, Bacteroides fragilis, Bacteroides distasonis, Bacteroides vulgatus, Clostridium leptum, Clostridium coccoides, Staphylococcus aureus, Bacillus subtilis, Clostridium butyricum, Brevibacterium lactofermentum, Streptococcus agalactiae, Lactococcus lactis, Leuconostoc lactis, Actinobacillus actinobycetemcomitans, cyanobacteria, Escherichia coli, Helicobacter pylori, Selnomonas ruminatium, Shigella sonnei, Zymomonas mobilis, Mycoplasma mycoides, Treponema denticola, Bacillus thuringiensis, Staphilococcus lugdunensis, Leuconost
  • the targeted bacteria are Escherichia coli.
  • bacteriophages used for preparing the bacterial virus particles, and then the bacterial virus particles may target (e.g., specifically target) a bacterial cell from any one or more of the foregoing genus and/or species of bacteria to specifically deliver the payload.
  • the targeted bacteria are pathogenic bacteria.
  • the targeted bacteria can be virulent bacteria.
  • the targeted bacteria can be antibacterial resistance bacteria, preferably selected from the group consisting of extended-spectrum beta-lactamase-producing (ESBL) Escherichia coli , ESBL Klebsiella pneumoniae , vancomycin-resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant (MDR) Acinetobacter baumannii , MDR Enterobacter spp., and a combination thereof.
  • the targeted bacteria can be selected from the group consisting of extended-spectrum beta-lactamase-producing (ESBL) Escherichia coli strains.
  • the targeted bacterium can be a bacterium of the microbiome of a given species, preferably a bacterium of the human microbiota.
  • the bacterial virus particles are prepared from bacterial virus.
  • the bacterial viruses are chosen in order to be able to introduce the payload into the targeted bacteria.
  • Bacterial viruses are preferably bacteriophages. Bacteriophage are obligate intracellular parasites that multiply inside bacteria by co-opting some or all of the host biosynthetic machinery. Phage genomes come in a variety of sizes and shapes (e.g., linear or circular). Most phages range in size from 24-200 nm in diameter. Phages contain nucleic acid (i.e., genome) and proteins, and may be enveloped by a lipid membrane. Depending upon the phage, the nucleic acid genome can be either DNA or RNA, and can exist in either circular or linear forms. The size of the phage genome varies depending upon the phage.
  • the simplest phages have genomes that are only a few thousand nucleotides in size, while the more complex phages may contain more than 100,000 nucleotides in their genome, and in rare instances more than 1,000,000.
  • the number and amount of individual types of protein in phage particles will vary depending upon the phage.
  • the bacteriophage is selected from the Order Caudovirales consisting of, based on the taxonomy of Krupovic et al, Arch Virol, 2015:
  • the bacteriophage is not part of the Order Caudovirales but from families with Unassigned order such as, without limitation, family Tectiviridae (such as genus Alphatectivirus, Betatectivirus), family Corticoviridae (such as genus Corticovirus), family Inoviridae (such as genus Fibrovirus, Habenivirus, Inovirus, Lineavirus, Plectrovirus, Saetivirus, Vespertiliovirus), family Cystoviridae (such as genus Cystovirus ), family Leviviridae (such as genus Allolevivirus, Levivirus), family Microviridae (such as genus Alpha3microvirus, G4microvirus, Phix174microvirus, Bdellomicrovirus, Chlamydiamicrovirus, Spiromicrovirus) and family Plasmaviridae (such as genus Plasmavirus ).
  • family Tectiviridae such as genus Alphatectivirus, Betatect
  • the bacteriophage is targeting Archea not part of the Order Caudovirales but from families with Unassigned order such as, without limitation, Ampullaviridae, FuselloViridae, Globuloviridae, Guttaviridae, Lipothrixviridae, Pleolipoviridae, Rudiviridae, Salterprovirus and Bicaudaviridae.
  • Bacteria of the genus Actinomyces can be infected by the following phages: Av-I, Av-2, Av-3, BF307, CT1, CT2, CT3, CT4, CT6, CT7, CT8 and 1281.
  • Bacteria of the genus Bacillus can be infected by the following phages: A, aiz1, A1-K-I, B, BCJA1, BC1, BC2, BLL1, BL1, BP142, BSL1, BSL2, BS1, BS3, BS8, BS15, BS18, BS22, BS26, BS28, BS31, BS104, BS105, BS106, BTB, B1715V1, C, CK-I, Coll, Corl, CP-53, CS-I, CSi, D, D, D, D5, ent1, FPB, FP9, FSi, FS2, FS3, FS5, FS8, FS9, G, GH8, GT8, GV-I, GV-2, GT-4, g3, g12, g13, g14, g16, g17, g21, g23, g24, g29, H2, ken1, KK-88, Kum1, Kyu1,
  • Bacillus -specific phages are defective: DLP10716, DLP-11946, DPB5, DPB12, DPB21, DPB22, DPB23, GA-2, M, No. IM, PBLB, PBSH, PBSV, PBSW, PBSX, PBSY, PBSZ, phi, SPa, type 1 and ⁇ .
  • Bacteria of the genus Bacteroides can be infected by the following phages: ad I2, Baf-44, Baf-48B, Baf-64, Bf-I, Bf-52, B40-8, F1, ⁇ 1, ⁇ A1, ⁇ BrO1, ⁇ BrO2, 11, 67.1, 67.3, 68.1, mt- Bacteroides (3), Bf42, Bf71, HN-Bdellovibrio (1) and BF-41.
  • Bacteria of the genus Bordetella can be infected by the following phages: 134 and NN- Bordetella (3).
  • Bacteria of the genus Borrellia can be infected by the following phages: NN- Borrelia (1) and NN- Borrelia (2).
  • Bacteria of the genus Burkholderia can be infected by the following phages: CP75, NN- Burkholderia (1) and 42.
  • Bacteria of the genus Chlamydia can be infected by the following phage: Chp1.
  • Bacteria of the genus Enterococcus are infected by the following phage: DF78, F1, F2, 1, 2, 4, 14, 41, 867, D1, SB24, 2BV, 182, 225, C2, C2F, E3, E62, DS96, H24, M35, P3, P9, SB1O1, S2, 2B II, 5, 182a, 705, 873, 881, 940, 1051, 1057, 21096C, NN- Enterococcus (1), PE1, F1, F3, F4, VD13, 1, 200, 235 and 341.
  • Bacteria of the genus Erysipelothrix can be infected by the following phage: NN- Eiysipelothrix (1).
  • Bacteria of the genus Fusobacterium are infected by the following phage: NN- Fusobacterium (2), fv83-554/3, fv88-531/2, 227, fv2377, fv2527 and fv8501.
  • Bacteria of the genus Haemophilus are infected by the following phage: HP1, S2 and N3.
  • Bacteria of the genus Helicobacter are infected by the following phage: HP1 and ⁇ circumflex over ( ) ⁇ circumflex over ( ) ⁇ - Helicobacter (1).
  • Bacteria of the genus Lepitospira are infected by the following phage: LE1, LE3, LE4 and ⁇ NN- Leptospira (1).
  • Bacteria of the genus Morganella are infected by the following phage: 47.
  • Bacteria of the genus Neisseria are infected by the following phage: Group I, group II and NP1.
  • Bacteria of the genus Nocardia are infected by the following phage: MNP8, NJ-L, NS-8, N5 and TtiN- Nocardia.
  • Bacteria of the genus Proteus are infected by the following phage: Pm5, 13vir, 2/44, 4/545, 6/1004, 13/807, 20/826, 57, 67b, 78, 107/69, 121, 9/0, 22/608, 30/680, PmI, Pm3, Pm4, Pm6, Pm7, Pm9, PmIO, PmI1, Pv2, ⁇ 1, ⁇ m, 7/549, 9B/2, 10A/31, 12/55, 14, 15, 16/789, 17/971, 19A/653, 23/532, 25/909, 26/219, 27/953, 32A/909, 33/971, 34/13, 65, 5006M, 7480b, VI, 13/3a, Clichy 12, ⁇ 2600, ⁇ 7, 1/1004, 5/742, 9, 12, 14, 22, 24/860, 2600/D52, Pm8 and 24/2514.
  • Bacteria of the genus Providencia are infected by the following phage: PL25, PL26, PL37, 9211/9295, 9213/921 Ib, 9248, 7/R49, 7476/322, 7478/325, 7479, 7480, 9000/9402 and 9213/921 Ia.
  • Bacteria of the genus Rickettsia are infected by the following phage: NN- Rickettsia.
  • Bacteria of the genus Serratia are infected by the following phage: A2P, PS20, SMB3, SMP, SMP5, SM2, V40, V56, ic, ⁇ CP-3, ⁇ CP-6, 3M, 10/1a, 20A, 34CC, 34H, 38T, 345G, 345P, 501B, SMB2, SMP2, BC, BT, CW2, CW3, CW4, CW5, Lt232, L2232, L34, L.228, SLP, SMPA, V.43, ⁇ , ⁇ CW1, ⁇ CP6-1, ⁇ CP6-2, ⁇ CP6-5, 3T, 5, 8, 9F, 10/1, 2OE, 32/6, 34B, 34CT, 34P, 37, 41, 56, 56D, 56P, 6OP, 61/6, 74/6, 76/4, 101/8900, 226, 227, 228, 229F, 286, 289, 290F, 512, 764a, 2847/10, 2847
  • Bacteria of the genus Treponema are infected by the following phage: NN- Treponema (1).
  • Bacteria of the genus Yersinia are infected by the following phage: H, H-I, H-2, H-3, H-4, Lucas 110, Lucas 303, Lucas 404, YerA3, YerA7, YerA20, YerA41, 3/M64-76, 5/G394-76, 6/C753-76, 8/C239-76, 9/F18167, 1701, 1710, PST, 1/F2852-76, D'Herelle, EV, H, Kotljarova, PTB, R, Y, YerA41, ⁇ NerO3-12, 3, 4/C1324-76, 7/F783-76, 903, 1/M6176 and Yer2AT.
  • the bacteriophage is selected in the group consisting of Salmonella virus SKML39, Shigella virus AG3, Dickeya virus Limestone, Dickeya virus RC2014, Escherichia virus CBA120, Escherichia virus PhaxI, Salmonella virus 38, Salmonella virus Det7, Salmonella virus GG32, Salmonella virus PM10, Salmonella virus SFP10, Salmonella virus SH19, Salmonella virus SJ3 , Escherichia virus ECML4, Salmonella virus Marshall, Salmonella virus Maynard, Salmonella virus SJ2 , Salmonella virus STML131, Salmonella virus ViI, Erwinia virus Ea2809, Klebsiella virus 0507KN21, Serratia virus IME250, Serratia virus MAM1, Campylobacter virus CP21, Campylobacter virus CP220, Campylobacter virus CPt10, Campylobacter virus IBB35, Campylobacter virus CP81, Campylobacter
  • the bacterial virus particles target E. coli and includes the capsid of a bacteriophage selected in the group consisting of BW73, B278, D6, D108, E, E1, E24, E41, FI-2, FI-4, FI-5, HI8A, Ff18B, i, MM, Mu, 025, PhI-5, Pk, PSP3, P1, P1D, P2, P4, S1, W ⁇ , ⁇ K13, ⁇ 1, ⁇ 2, ⁇ 7, ⁇ 92, 7 A, 8 ⁇ , 9 ⁇ , 18, 28-1, 186, 299, HH- Escherichia (2), AB48, CM, C4, C16, DD-VI, E4, E7, E28, FI1, FI3, H, H1, H3, H8, K3, M, N, ND-2, ND-3, ND4, ND-5, ND6, ND-7, Ox-I, Ox-2, Ox-3, Ox-4, Ox-5, Ox-6, PhI-I, RB
  • the bacterial delivery vehicle is a bacterial virus particle.
  • the payload may be a plasmid.
  • the invention may concern a bacterial virus particle with the plasmid according to the invention as disclosed hereabove (in particular it comprises at least two packaging sites) encapsidated into the particle. It also relates to a combination of at least two different bacterial virus particles, said different bacterial virus particles having the same plasmid encapsidated into the particles.
  • the different bacterial delivery vehicles are capable of targeting at least two different bacteria and of introducing the plasmid into said bacteria.
  • the different bacterial virus particles are capable of targeting the same bacteria and of introducing the payload into said bacteria.
  • the spectra of the population of bacterial virus particles is defined according to the bacteriophages infection spectra, as describe hereabove.
  • the particles may comprise the capsid of bacteriophages selected of in the group consisting of lambda derived capsids, P4 derived capsids, M13-derived capsids, P1 derived capsids (see, e.g., Westwater C A et al., Microbiology 148, 943-50 (2002); Kittleson J T et al., ACS Synthetoc Biology 1, 583-89 (2012); Mead D A et al, Biotechnology 10, 85-102 (1988)).
  • the phagemid is selected from the group consisting of lambda derived phagemids, P4 derived phagemids, M13-derived phagemids, such as the ones containing the fl origin for filamentous phage packaging such as, for example, pBluescript II SK (+/ ⁇ ) and KS (+/ ⁇ ) phagemids, pBC SK and KS phagemids, pADL and P1 derived phagemids, preferably phagemids according to the invention are selected from lambda derived phagemids and P4 derived phagemids, more preferably, phagemids according to the invention are selected from lambda derived phagemids, preferably selected from the group consisting of HK022 derived phagemids, mEP237 derived phagemids, HK97 derived phagemids, HK629 derived phagemids, HK630 derived phagemids,
  • the bacterial delivery vehicles comprise the capsid of bacteriophages selected in the group consisting of P2, P4, ⁇ , and 186.
  • the bacterial delivery vehicles comprise the capsid of bacteriophages P2 and ⁇ .
  • the bacterial delivery vehicles may comprise the capsid of bacteriophages selected from lambda derived capsids, preferably selected from the group consisting of HK022 derived capsids, mEP237 derived capsids, HK97 derived capsids, HK629 derived capsids, HK630 derived capsids, mEP043 derived capsids, mEP213 derived capsids, mEP234 derived capsids, mEP390 derived capsids, mEP460 derived capsids, mEPx1 derived capsids, mEPx2 derived capsids, phi80 derived capsids, mEP234 derived capsids.
  • lambda derived capsids preferably selected from the group consisting of HK022 derived capsids, mEP237 derived capsids, HK97 derived capsids, HK629
  • a method for preparing a population of at least two different bacterial virus particles containing the same payload.
  • the method comprises the introduction of the payload according to the invention into bacteria, the production bacteria.
  • the bacteria can be infected (i.e. according to the bacteriophage spectra known by the person skilled in the art).
  • the bacteria can be transfected by the payload according to the invention.
  • the bacterium is suitable for the replication of the payload according to the invention and its packaging into at least one of the different bacterial delivery vehicles.
  • the bacteria may further comprise satellite or helper phages genes to promote the packaging of the payload.
  • the bacteria express the structural and functional proteins necessary to promote an in vitro packaging of the payload in a bacterial delivery vehicle, particularly in a bacterial virus particle.
  • the bacteria express the protein of the particle, namely the capsid or coat proteins.
  • a first bacterium is used for producing the payload packaged into a first bacterial delivery vehicle and a second bacterium is used for producing the same payload packaged into a second bacterial virus particle. Then, for each bacterial virus particle, a specific bacterium is used for the production of the payload packaged into a particular bacterial virus particle. Accordingly, each specific bacterium comprises satellite or helper phage genes to promote the packaging of the payload into the particular bacterial virus particle.
  • the first bacterium expresses the structural and functional proteins necessary to promote an intracellular (i.e.
  • the first bacterium expresses the capsid or coat proteins of a first bacterial virus particle; and the second bacterium expresses the capsid or coat proteins of a second bacterial virus particle.
  • the present invention also relates to a kit comprising such a first and second bacteria and so on.
  • one bacterium is used for producing the payload packaged into a first bacterial delivery vehicle and a second bacterial delivery vehicle. Then, for a combination of at least two bacterial delivery vehicles, a bacterium is used for the production of the payload packaged into at least two different bacterial delivery vehicles.
  • a bacterium comprises satellite or helper phages genes to promote the packaging of the payload into at least two different bacterial delivery vehicles, preferably into at least two different bacterial virus particles.
  • the bacterium expresses the structural and functional proteins necessary to promote an intracellular packaging of the payload into a first bacterial delivery vehicle and a second bacterial virus particle.
  • the bacterium expresses the capsid or coat proteins of a first bacterial virus particle and of a second bacterial virus particle.
  • the capsid or coat proteins of a first bacterial virus particle and of a second bacterial virus particle.
  • the method comprises:
  • the method may further comprise a step of recovering the bacterial delivery vehicles having the payload packaged into them.
  • the introduction of the payload into bacteria can be carried out by transfection or by injection.
  • Such methods may further comprise the use of a helper phage to promote the packaging in at least two different delivery vehicles. It is known by the person skilled in the art that some bacteriophages are defective and need a helper phage for replication and/or packaging. Thus, compatible pairs of principal phage and helper phage are easily made by the person skilled in the art to promote an efficient payload packaging.
  • Helper phage can be but are not limited to M13KO7, R408, VCSM13, KM13 (Res Microbiol (2001) 152, 187-191), M13MDD3.2 (FEMS Microbiol Lett (1995) 125, 317-321), R408d3 (Gene (1997) 198, 99-103), VCSM13d3 (Gene (1997) 198, 99-103), Hyperphage (Nat Biotechnol (2001) 19, 75-78), CT helper phage (Nucleic Acids Res (2003) 31, e59), Ex-phage (Nucleic Acids Res (2002) 30, e18), Phaberge (J Immunol Methods (2003) 274, 233-244), XP5 (J Immunol Methods (2012) 376, 46-54), DeltaPhage (Nucleic Acids Res (2012) 40, e120).
  • a bacterial strain carrying a helper phage derivative that expresses all the components required for encapsidation may also be used.
  • such methods further comprise the use of a satellite phage.
  • the satellite phages can encode proteins that promote capsid size reduction of the principal phage, as described for the P4 Sid protein that controls the P2 capsid size to fit its smaller genome.
  • Such satellite phage can for example be phages P4.
  • such methods further comprise the use of P4 satellite phage proteins, preferably the Sid protein, to promote the encapsidation of the payload in P2 bacterial virus capsid.
  • the bacterial delivery vehicle i.e. bacterial virus particle
  • the bacterial delivery vehicle can be produced in vitro by contacting the payload with the structural and functional proteins necessary to promote an in vitro packaging of the payload into a particular bacterial virus particle (Hohn et al, PNAS, 1977)(Collins et al, PNAS, 1978)(Gunther et al, NAR, 1993)
  • the present invention also relates to a kit comprising the payload as disclosed herein, optionally a satellite phage and/or a helper phage to promote the packaging of the payload in the at least two bacteria delivery vehicles and optionally bacterial cells suitable for packaged payload production.
  • the kit further comprises a satellite phage and/or a helper phage to promote the packaging of the payload in the at least two bacteria delivery vehicles.
  • the kit further comprises a Helper phage selected in the group consisting of M13KO7, R408, VCSM13, KM13 (Res Microbiol (2001) 152, 187-191), M13MDD3.2 (FEMS Microbiol Lett (1995) 125, 317-321), R408d3 (Gene (1997) 198, 99-103), VCSM13d3 (Gene (1997) 198, 99-103), Hyperphage (Nat Biotechnol (2001) 19, 75-78), CT helper phage (Nucleic Acids Res (2003) 31, e59), Ex-phage (Nucleic Acids Res (2002) 30, e18), Phaberge (J Immunol Methods (2003) 274, 233-244), XP5 (J Immunol Methods (2012) 376, 46-54), DeltaPhage (Nucleic Acids Res (2012) 40, e120).
  • a Helper phage selected in the group consisting of M13KO7, R408, VCSM13, KM
  • the kit further comprises a satellite phage or satellite phage genes.
  • the satellite phages can encode proteins that promote capsid size reduction of the principal phage, as described for the P4 Sid protein that controls the P2 capsid size to fit its smaller genome.
  • the kit further comprises vials containing natural or non-natural bacterial host cells suitable for packaged payload production.
  • the kit further comprises bacterial cells suitable for packaged payload production selected in the group consisting of Actinomyces, Achromobacter, Acidaminococcus, Acinetobacter, Aeromonas, Alcaligenes, Bacillus, Bacteroides, Bifidobacterium, Bordetella, Borrelia, Brucella, Burkholderia, Butyriviberio, Campylobacter, Chlamydia, Citrobacter, Clostridium, Corynebacterium, Eikenella, Enterobacter, Enterococcus, Erysipelothrix, Escherichia, Eubacterium, Flavobacterium, Francisella, Fusobacterium, Haemophilus, Helicobacter, Klebsiella, Lactobacillus, Legionella, Leptospira, Listeria, Methanobrevibacter, Morganella, Mycobacterium, Mycoplamsa, Neisseria, Nocardia, Peptococcus, Prevotell
  • the bacteria carry a helper phage or a satellite phage derivative that expresses all the components required for the payload packaging.
  • the bacterial host cells are E. coli.
  • the kit may further comprise one or more of wash buffers and/or reagents, hybridization buffers and/or reagents, labelling buffers and/or reagents, and detection means.
  • the buffers and/or reagents are usually optimized for the particular utilization for which the kit is intended. Protocols for using these buffers and reagents for performing different steps of the procedure may also be included in the kit. Further optional components of the kits may include expression media with different supply (antibiotics or nutriment) for bacteria growth and/or selection of bacteria containing the payload of the invention.
  • the present invention relates to a pharmaceutical or veterinary composition comprising the payload as described hereabove packaged into a bacterial delivery vehicle. More particularly, the present invention relates to a pharmaceutical or veterinary composition comprising the payload described hereabove packaged into at least two different bacterial delivery vehicles.
  • the present invention relates to a pharmaceutical or veterinary composition
  • a pharmaceutical or veterinary composition comprising at least two different bacterial virus particles with the same payload as described hereabove packaged into them.
  • the at least two different bacterial virus particles can be prepared from any of the above described bacteriophages.
  • the pharmaceutical composition comprising at least two bacterial virus particles capable of targeting at least two different bacteria and of introducing the payload into the bacteria.
  • the pharmaceutical composition comprising at least two bacterial virus particles capable of targeting the same bacterium and of introducing the payload into this bacterium.
  • the pharmaceutical composition comprises several bacterial delivery vehicles with the same payload according to the present invention and/or bacterial delivery vehicles with different payload inside.
  • composition comprising different bacterial delivery vehicles with the same payload inside
  • ELISA protein detection and quantification assays
  • a cocktail or mixture of bacterial delivery vehicles can be developed that contain identical DNA payloads with the exception of a unique “tracer” sequence designed in such a way that all the payloads packaged in a same delivery vehicles have the same “tracer” sequence and payloads packaged in different delivery vehicles have different “tracer” sequences.
  • the tracer is composed of two nucleic acid constant regions flanking one nucleic acid variable region. Each region of the tracer can be of any length, and more preferably between 25 and 50 nucleotides each.
  • the mixture of delivery vehicles contains delivery vehicles comprising different DNA payloads, each DNA payload comprising different tracer or the same tracer, in order to allow detection of each delivery vehicles and determination of their relative abundance.
  • compositions according to the invention can be formulated for any conventional route of administration including a topical, enteral, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous or intraocular administration and the like, preferably enteral, oral, or inhalation routes.
  • the pharmaceutical or veterinary composition according to the invention can be administered by any conventional route of administration including a topical, enteral, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous or intraocular administration and the like, preferably enteral, oral, intranasal or inhalation routes.
  • the pharmaceutical or veterinary composition according to the invention may be administered by enteral or parenteral route of administration.
  • the pharmaceutical or veterinary composition according to the invention is preferably administered by intravenous route of administration.
  • the pharmaceutical or veterinary composition according to the invention is preferably administered by oral route of administration.
  • the pharmaceutical or veterinary composition can be formulated into conventional oral dosage forms such as tablets, capsules, powders, granules and liquid preparations such as syrups, elixirs, and concentrated drops.
  • Nontoxic solid carriers or diluents may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like.
  • binders which are agents which impart cohesive qualities to powdered materials, are also necessary.
  • starch, gelatin, sugars such as lactose or dextrose, and natural or synthetic gums can be used as binders.
  • Disintegrants are also necessary in the tablets to facilitate break-up of the tablet.
  • Disintegrants include starches, clays, celluloses, algins, gums and crosslinked polymers.
  • lubricants and glidants are also included in the tablets to prevent adhesion to the tablet material to surfaces in the manufacturing process and to improve the flow characteristics of the powder material during manufacture.
  • Colloidal silicon dioxide is most commonly used as a glidant and compounds such as talc or stearic acids are most commonly used as lubricants.
  • the pharmaceutical or veterinary composition can be formulated into ointment, cream or gel form and appropriate penetrants or detergents could be used to facilitate permeation, such as dimethyl sulfoxide, dimethyl acetamide and dimethylformamide.
  • nasal sprays for transmucosal administration, nasal sprays, rectal or vaginal suppositories can be used.
  • the active compounds can be incorporated into any of the known suppository bases by methods known in the art. Examples of such bases include cocoa butter, polyethylene glycols (carbowaxes), polyethylene sorbitan monostearate, and mixtures of these with other compatible materials to modify the melting point or dissolution rate.
  • compositions according to the invention may be formulated to release the active ingredients substantially immediately upon administration or at any predetermined time or time period after administration.
  • the pharmaceutical or veterinary composition according to the invention further comprises another active ingredient.
  • the additional active ingredient can be a prebiotic, a probiotic, an antibiotic, another antibacterial or antibiofilm agent and/or any agent enhancing the binding of the delivery particle on the bacteria and/or the delivery of the payload to the bacteria.
  • Prebiotics include, but are not limited to, amino acids, biotin, fructo-oligosaccharide, galacto-oligosaccharides, hemicelluloses (e.g., arabinoxylan, xylan, xyloglucan, and glucomannan), inulin, chitin, lactulose, mannan oligosaccharides, oligofructose-enriched inulin, gums (e.g., guar gum, gum arabic and carregenaan), oligofructose, oligodextrose, tagatose, resistant maltodextrins (e.g., resistant starch), trans-galactooligosaccharide, pectins (e.g., xylogalactouronan, citrus pectin, apple pectin, and rhamnogalacturonan-I), dietary fibers (e.g., soy fiber, sugarbeet fiber,
  • Probiotics include, but are not limited to lactobacilli, bifidobacteria, streptococci, enterococci, propionibacteria, saccaromycetes, lactobacilli, bifidobacteria, or proteobacteria.
  • the antibiotic can be selected from the group consisting in penicillins such as penicillin G, penicillin K, penicillin N, penicillin O, penicillin V, methicillin, benzylpenicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin, epicillin, carbenicillin, ticarcillin, temocillin, mezlocillin, and piperacillin; cephalosporins such as cefacetrile, cefadroxil, cephalexin, cefaloglycin, cefalonium, cefaloridine, cefalotin, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefradine, cefroxadine, ceftezole, cefaclor, cefonicid
  • the pharmaceutical or veterinary composition according to the invention may further comprise a pharmaceutically acceptable vehicle.
  • a solid pharmaceutically acceptable vehicle may include one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tablet-disintegrating agents.
  • Suitable solid vehicles include, for example calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • the pharmaceutical or veterinary composition may be prepared as a sterile solid composition that may be suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.
  • the pharmaceutical or veterinary compositions of the invention may be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 8o (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
  • the particles according to the invention can also be administered orally either in liquid or solid composition form.
  • compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions.
  • forms useful for enteral administration include sterile solutions, emulsions, and suspensions.
  • the bacterial virus particles according to the invention may be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
  • a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
  • the liquid vehicle can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators.
  • suitable examples of liquid vehicles for oral and enteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g.
  • the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid vehicles are useful in sterile liquid form compositions for enteral administration.
  • the liquid vehicle for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.
  • the pharmaceutical or veterinary composition can be formulated into ointment, cream or gel form and appropriate penetrants or detergents could be used to facilitate permeation, such as dimethyl sulfoxide, dimethyl acetamide and dimethylformamide.
  • nasal sprays for transmucosal administration, nasal sprays, rectal or vaginal suppositories can be used.
  • the active compounds can be incorporated into any of the known suppository bases by methods known in the art. Examples of such bases include cocoa butter, polyethylene glycols (carbowaxes), polyethylene sorbitan monostearate, and mixtures of these with other compatible materials to modify the melting point or dissolution rate.
  • the pharmaceutical or veterinary composition, the bacterial virus particles as disclosed above and the combination of at least two different bacterial virus particles having the same payload can be used as a medicament.
  • the present invention relates to the pharmaceutical or veterinary composition, the bacterial virus particles as disclosed above and the combination of at least two different bacterial virus particles having the same payload for use in the treatment of a disorder or a disease caused by a bacterium, to the use of the pharmaceutical or veterinary composition, the bacterial virus particles as disclosed above and the combination of at least two different bacterial virus particles having the same payload for the manufacture of a medicament useful in the treatment of a disorder or a disease caused by a bacterium; and to a method for treating a disorder or a disease caused by a bacterium comprising the administration of a therapeutically effective amount of the pharmaceutical or veterinary composition, the bacterial virus particles as disclosed above and the combination of at least two different bacterial virus particles having the same payload.
  • diseases or disorders include an infection, preferably a bacterial infection, inflammatory diseases, auto-immune diseases, cancers, metabolic disorders and brain disorders.
  • the bacterial virus particles only target the bacterial strain responsible of the disease or disorder and thus allow the subject to be treated to conserve a healthy microbiome.
  • the diseases or disorders caused by bacteria may be selected from the group consisting of abdominal cramps, acne vulgaris, acute epiglottitis, arthritis, bacteraemia, bloody diarrhea, botulism, Brucellosis, brain abscess, chancroid venereal disease, Chlamydia , Crohn's disease, conjunctivitis, cholecystitis, colorectal cancer, polyposis, dysbiosis, Lyme disease, diarrhea, diphtheria, duodenal ulcers, endocarditis, erysipelothricosis, enteric fever, fever, glomerulonephritis, gastroenteritis, gastric ulcers, Guillain-Barre syndrome tetanus, gonorrhoea, gingivitis, inflammatory bowel diseases, irritable bowel syndrome, leptospirosis, leprosy, listeriosis, tuberculosis, Lady Widermere syndrome, Legionaire's disease, meningitis,
  • the infection caused by bacteria may be selected from the group consisting of skin infections such as acne, intestinal infections such as esophagitis, gastritis, enteritis, colitis, sigmoiditis, rectitis, and peritonitis, urinary tract infections, vaginal infections, female upper genital tract infections such as salpingitis, endometritis, oophoritis, myometritis, parametritis and infection in the pelvic peritoneum, respiratory tract infections such as pneumonia, intra-amniotic infections, odontogenic infections, endodontic infections, fibrosis, meningitis, bloodstream infections, nosocomial infection such as catheter-related infections, hospital acquired pneumonia, post-partum infection, hospital acquired gastroenteritis, hospital acquired urinary tract infections, or a combination thereof.
  • the infection according to the invention is caused by a bacterium presenting an antibiotic resistance.
  • the infection is caused by a bacterium as listed above in the targeted bacteria.
  • the metabolic disorder includes obesity and diabetes.
  • the invention concerns a pharmaceutical or veterinary composition for use in the treatment of pathologies involving bacteria of the human microbiome, such as inflammatory and auto-immune diseases, cancers, infections or brain disorders.
  • bacteria of the human microbiome such as inflammatory and auto-immune diseases, cancers, infections or brain disorders.
  • some bacteria of the microbiome without triggering any infection, can secrete molecules that will induce and/or enhance inflammatory or auto-immune diseases or cancer development.
  • the present invention relates also to modulating microbiome composition to improve the efficacy of immunotherapies based, for example, on CAR-T (Chimeric Antigen Receptor T) cells, TIL (Tumor Infiltrating Lymphocytes) and Tregs (Regulatory T cells) also known as suppressor T cells.
  • CAR-T Chimeric Antigen Receptor T
  • TIL Tuor Infiltrating Lymphocytes
  • Tregs Regulatory T cells
  • Modulation of the microbiome composition to improve the efficacy of immunotherapies may also include the use of immune checkpoint inhibitors well known in the art such as, without limitation, PD-1 (programmed cell death protein 1) inhibitor, PD-L1 (programmed death ligand 1) inhibitor and CTLA-4 (cytotoxic T lymphocyte associated protein 4).
  • immune checkpoint inhibitors well known in the art such as, without limitation, PD-1 (programmed cell death protein 1) inhibitor, PD-L1 (programmed death ligand 1) inhibitor and CTLA-4 (cytotoxic T lymphocyte associated protein 4).
  • Some bacteria of the microbiome can also secrete molecules that will affect the brain.
  • a further object of the invention is a method for controlling the microbiome of a subject, comprising administering an effective amount of the pharmaceutical composition as disclosed herein in said subject.
  • the invention also relates to a method for personalized treatment for an individual in need of treatment for a bacterial infection comprising: i) obtaining a biological sample from the individual and determining a group of bacterial DNA sequences from the sample; ii) based on the determining of the sequences, identifying one or more pathogenic bacterial strains or species that were in the sample; and iii) administering to the individual a pharmaceutical composition according to the invention comprising a combination of at least two bacterial virus particles capable of recognizing each pathogenic bacterial strain or species identified in the sample and to deliver the packaged payload.
  • the biological sample comprises pathological and non-pathological bacterial species, and subsequent to administering the pharmaceutical or veterinary composition according to the invention to the individual, the amount of pathogenic bacteria on or in the individual are reduced, but the amount of non-pathogenic bacteria is not reduced.
  • the invention concerns a pharmaceutical or veterinary composition according to the invention for use in order to improve the effectiveness of drugs.
  • some bacteria of the microbiome without being pathogenic by themselves, are known to be able to metabolize drugs and to modify them in ineffective or harmful molecules.
  • the invention concerns the in-situ bacterial production of any compound of interest, including therapeutic compound such as prophylactic and therapeutic vaccine for mammals.
  • the compound of interest can be produced inside the targeted bacteria, secreted from the targeted bacteria or expressed on the surface of the targeted bacteria.
  • an antigen is expressed on the surface of the targeted bacteria for prophylactic and/or therapeutic vaccination.
  • the present invention also relates to a non-therapeutic use of the bacterial virus particles as disclosed above and the combination of at least two different bacterial virus particles having the same payload according to the invention.
  • the non-therapeutic use can be a cosmetic use or a use for improving the well-being of a subject, in particular a subject who does not suffer from a disease.
  • the present invention also relates to a cosmetic composition or a non-therapeutic composition comprising the bacterial virus particles as disclosed above and the combination of at least two different bacterial virus particles having the same payload according to the invention.
  • the subject according to the invention is an animal, preferably a mammal, even more preferably a human.
  • the term “subject” can also refer to non-human animals, in particular mammals such as dogs, cats, horses, cows, pigs, sheep, donkeys, rabbits, ferrets, gerbils, hamsters, chinchillas, rats, mice, guinea pigs and non-human primates, among others, or non-mammals such as poultry, that are in need of treatment.
  • the human subject according to the invention may be a human at the prenatal stage, a new-born, a child, an infant, an adolescent or an adult at any age.
  • the subject has been diagnosed with, or is at risk of developing an infection, a disorder and/or a disease preferably due to a bacterium. Diagnostic method of such infection, disorder and/or disease are well known by the man skilled in the art.
  • the infection, disorder and/or disease presents a resistance to treatment, preferably the infection, disorder or disease presents an antibiotic resistance.
  • the subject has never received any treatment prior to the administration of the delivery vehicles according to the invention, preferably a payload according to the invention, particularly a payload packaged into a delivery vehicle according to the invention, preferably a packaged plasmid or phagemid into a bacterial virus particle according to the invention, or of a pharmaceutical or veterinary composition according to the invention.
  • a payload according to the invention particularly a payload packaged into a delivery vehicle according to the invention, preferably a packaged plasmid or phagemid into a bacterial virus particle according to the invention, or of a pharmaceutical or veterinary composition according to the invention.
  • the subject has already received at least one line of treatment, preferably several lines of treatment, prior to the administration of the delivery vehicles according to the invention, preferably a payload according to the invention, particularly a payload packaged into a delivery vehicle according to the invention, preferably a packaged plasmid or phagemid into a bacterial virus particle according to the invention, or of a pharmaceutical or veterinary composition according to the invention.
  • a payload according to the invention particularly a payload packaged into a delivery vehicle according to the invention, preferably a packaged plasmid or phagemid into a bacterial virus particle according to the invention, or of a pharmaceutical or veterinary composition according to the invention.
  • the treatment is administered regularly, preferably between every day and every month, more preferably between every day and every two weeks, more preferably between every day and every week, even more preferably the treatment is administered every day.
  • the treatment is administered several times a day, preferably 2 or 3 times a day, even more preferably 3 times a day.
  • the duration of treatment with delivery vehicles according to the invention is preferably comprised between 1 day and 20 weeks, more preferably between 1 day and 10 weeks, still more preferably between 1 day and 4 weeks, even more preferably between 1 day and 2 weeks.
  • the duration of the treatment is of about 1 week.
  • the treatment may last as long as the infection, disorder and/or disease persists.
  • the form of the pharmaceutical or veterinary compositions, the route of administration and the dose of administration of delivery vehicles according to the invention, preferably of a payload according to the invention, particularly of a payload packaged into a delivery vehicle according to the invention, preferably of a packaged plasmid or phagemid into a bacterial virus particle according to the invention, or of a pharmaceutical or veterinary composition according to the invention can be adjusted by the man skilled in the art according to the type and severity of the infection (e.g. depending on the bacteria species involved in the disease, disorder and/or infection and its localization in the patient's or subject's body), and to the patient or subject, in particular its age, weight, sex, and general physical condition.
  • the amount of delivery vehicles according to the invention preferably a payload according to the invention, particularly a payload packaged into a delivery vehicle according to the invention, preferably a packaged plasmid or phagemid into a bacterial virus particle according to the invention, or of a pharmaceutical or veterinary composition according to the invention, to be administered has to be determined by standard procedure well known by those of ordinary skills in the art. Physiological data of the patient or subject (e.g. age, size, and weight) and the routes of administration have to be taken into account to determine the appropriate dosage, so as a therapeutically effective amount will be administered to the patient or subject.
  • the total amount of delivery vehicles particularly a payload packaged into a delivery vehicle according to the invention, preferably a plasmid or phagemid packaged into a bacterial virus particle according to the invention, for each administration is comprised between 10 4 and 10 15 delivery vehicles.
  • P1-like (P1) P2-like (186) and lambdoid (lambda).
  • P1 relies on a headfull packaging system whereas both P2-like and Lambdoid rely on cohesive end packaging. Even if they use the same phage termini type (cohesive ends) lambdoid and P2-like use a different DNA substrate for the packaging.
  • lambdoid phages undergo rolling circle replication to generate a concatemer of the phage genome (head to tail repeat of the DNA), then the terminase bind on the packaging recognition site called cos, generate a double strand cleavage, get recruited on the procapsid and start to fulfill it in a unidirectional process until the next cos.
  • the preferred DNA substrate is a circular monomer, which is recognized by the terminase at the cos level and then cleaved and packaged. Consequently, a monomeric circular DNA molecule that is suitable for P2 packaging and can also get concatemerized for lambda packaging was used.
  • chromosomes are circularly permuted and contain terminally redundancy that allow recircularization of DNA upon injection. Then the packaging site called pac is recognized by the terminase (or pacase) that attaches to a procapsid and fulfill more than 100% of the genome and cut.
  • the plasmid includes a chloramphenicol resistance gene that allows scoring for transductant, a colE1 origin of replication, the Coi gene under the control of pBad that allows induction of the lytic cycle of P1, a cis element inside the cin gene of P1 and the P1 replication origin inside repL.
  • the three different lysogene cell lines containing the payload were induced to produce phagemids particles.
  • For the production cell line CY2120b and C600(186) ⁇ cos only phagemids particles and no phages were produced due to the deletion of the cos site from the prophages.
  • the entire test i.e. induction and titration, was performed in triplicate.
  • the graphs of FIG. 1 represent the mean of the phagemid particle concentration per ⁇ L obtained for each phagemids particles in 3 independent experiments as detailed in FIG. 2 .
  • the three different cell lines containing the payload were grown separately overnight in LB+chloramphenicol 25 ⁇ g/mL. The following day, cells were diluted 1/100 in 10 mL of LB and incubated at 30° C. with shaking. For strain CY2120b and C600(186) ⁇ cos the culture, at OD600 nm around 0.6, were shifted to 42° C. for 30 minutes to induce the entry into lytic cycle. After that, cells were shifted back to 37° C. for 2 hours (C600(186) ⁇ cos) or 3 hours (CY2120b) to allow virion assembly and packaging in either of the two capsids. Chlorophorm was added in the case of CY2120b to burst the cell. Cell lysate was filtered with 0.2 ⁇ m syringe filter.
  • the induction of the lytic cycle was performed by adding arabinose 0.2%. After 2 hours cell lysate was filtered with 0.2 ⁇ m syringe filter.
  • E. coli KL739 and E. coli K-12 MG1655 overnight culture in LB was diluted 1/100.
  • 90 ⁇ l of cells were incubated at 37° C. for 30 min with 10 ⁇ L of each phagemids diluted 1/100.
  • serial dilution of the samples were performed in PBS 1 ⁇ and all dilution were plated on LB supplemented with chloramphenicol 25 ⁇ g/mL. Plate were incubated at 37° C. overnight and the CFU counts done the day after.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US16/444,576 2018-06-20 2019-06-18 Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof Active 2039-06-22 US11124776B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/406,437 US11952594B2 (en) 2018-06-20 2021-08-19 Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof
US18/598,495 US20240209326A1 (en) 2018-06-20 2024-03-07 Bacterial delivery vehicle, process of production and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305781.9A EP3584316B1 (en) 2018-06-20 2018-06-20 Bacterial delivery vehicle, process of production and uses thereof
EP18305781.9 2018-06-20
EP18305781 2018-06-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/406,437 Continuation US11952594B2 (en) 2018-06-20 2021-08-19 Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof

Publications (2)

Publication Number Publication Date
US20190390175A1 US20190390175A1 (en) 2019-12-26
US11124776B2 true US11124776B2 (en) 2021-09-21

Family

ID=62909472

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/444,576 Active 2039-06-22 US11124776B2 (en) 2018-06-20 2019-06-18 Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof
US17/406,437 Active 2039-10-20 US11952594B2 (en) 2018-06-20 2021-08-19 Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof
US18/598,495 Pending US20240209326A1 (en) 2018-06-20 2024-03-07 Bacterial delivery vehicle, process of production and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US17/406,437 Active 2039-10-20 US11952594B2 (en) 2018-06-20 2021-08-19 Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof
US18/598,495 Pending US20240209326A1 (en) 2018-06-20 2024-03-07 Bacterial delivery vehicle, process of production and uses thereof

Country Status (5)

Country Link
US (3) US11124776B2 (da)
EP (2) EP3584316B1 (da)
DE (2) DE18305781T1 (da)
DK (2) DK3584316T1 (da)
WO (1) WO2019243373A1 (da)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230233299A1 (en) * 2022-01-27 2023-07-27 EdgeEndo, LLC Dental, endodontic, and periodontic treatment methods and systems
US11952594B2 (en) 2018-06-20 2024-04-09 Eligo Bioscience Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220233615A1 (en) * 2019-05-21 2022-07-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bacteriophages for the treatment of tuberculosis
EP3987047A1 (en) 2019-06-18 2022-04-27 Eligo Bioscience Bacterial delivery vehicles comprising tracer nucleic acid sequences
WO2023052628A1 (en) * 2021-10-01 2023-04-06 Eth Zurich Bacteriophages producing heterologous bacteriocins
CN114574467B (zh) * 2022-01-21 2023-05-23 华南农业大学 一种基因表达调控系统及其应用
WO2023212396A1 (en) * 2022-04-29 2023-11-02 The Board Of Trustees Of The Leland Stanford Junior University High capacity lentiviral vectors
WO2024003301A1 (en) * 2022-06-29 2024-01-04 Snipr Biome Aps Targeting e coli cells
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024194876A1 (en) * 2023-03-23 2024-09-26 Technion Research & Development Foundation Limited Bacteriophages as a tool to manipulate gut commensal immune-modulation activity
CN116676324B (zh) * 2023-07-28 2023-10-27 四川大学华西医院 基于Kil蛋白构建释放抗肿瘤效应蛋白的系统及方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920048A (en) 1984-12-12 1990-04-24 Novo Industri A/S Method for stabilizing extra-chromosomal elements in bacteria during cultivation
US5691185A (en) 1993-10-08 1997-11-25 Chr. Hansen A/S Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US6752994B2 (en) 1991-06-13 2004-06-22 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
WO2007141540A2 (en) * 2006-06-09 2007-12-13 Sinvent As Rk2-based broad-host-range cloning vector useful for transfer of metagenomic libraries to a variety of bacterial species
WO2008157515A1 (en) 2007-06-16 2008-12-24 Sacrab Genomics Nucleic acid packaging system
WO2014124226A1 (en) 2013-02-07 2014-08-14 The Rockefeller University Sequence specific antimicrobials
US20150064138A1 (en) 2013-09-05 2015-03-05 Massachusetts Institute Of Technology Tuning microbial populations with programmable nucleases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE18305781T1 (de) 2018-06-20 2020-09-17 Eligo Bioscience Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920048A (en) 1984-12-12 1990-04-24 Novo Industri A/S Method for stabilizing extra-chromosomal elements in bacteria during cultivation
US6752994B2 (en) 1991-06-13 2004-06-22 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
US5691185A (en) 1993-10-08 1997-11-25 Chr. Hansen A/S Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
WO2007141540A2 (en) * 2006-06-09 2007-12-13 Sinvent As Rk2-based broad-host-range cloning vector useful for transfer of metagenomic libraries to a variety of bacterial species
WO2008157515A1 (en) 2007-06-16 2008-12-24 Sacrab Genomics Nucleic acid packaging system
WO2014124226A1 (en) 2013-02-07 2014-08-14 The Rockefeller University Sequence specific antimicrobials
US20150064138A1 (en) 2013-09-05 2015-03-05 Massachusetts Institute Of Technology Tuning microbial populations with programmable nucleases

Non-Patent Citations (54)

* Cited by examiner, † Cited by third party
Title
Abudayyeh, O., et al. (2017) RNA targeting with CRISPR—Cas13. Nature 550, 280.
Beaber, et al., A new helper for improved monovalent display of Fab molecules, J Immunol Methods (2012) 376, 46-54.
Bikard et al., 2012, CRISPR Interference Can prevent Natural Transformation and Virulence Acquisition during In Vivo Bacterial Infection, Cell Host &Microbe 12, 177-186.
Bikard, et al., 2014, Development of Sequence-specific antimicrobials based on programmable CRISPR-Cas nucleases, Nat Biotech 11, vol. 32.
Cambray G et al, Measurement and Modeling of Intrinsic Transcription Terminators, (Nucl Acids Res, 2013, 41(9): 5139-5148).
Casjens, et al., Determining DNA Packaging Strategy by Analysis of the Termini of the Chromosomes in Tailed-Bacteriophage Virions, Methods Mol Biol. 502: 91-111 (2009).
Chen, et al., Characterization of 582 Natural and Synthetic Terminators and Quantification of their Design Constraints (2013), Nature Methods, 10: 659-664).
Chung, YB, et al., Bacteriophage T7 DNA Packaging, II. Analysis of the DNA Sequences Required for Packaging Using a Plasmid Transduction Assay, J Mol. Biol., 216:927-938 (1990).
Citorik, R et al, 2014, Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases, Nat Biotech 11,vol. 32, 1141-1145.
Collins, et al., (1978). Cosmids: A type of plasmid gene-cloning vector that is packageable in vitro in bacteriophage I heads. PNAS 75(9) : 4242-4246.
Cotter, et al., Bacteriocins—a viable alternative to antibiotics, Nature Reviews Microbiology 11: 95, 2013.
Cronan, J. Improved plasmid-based system for fully regulated off-to-on gene expression in Escherichia coli: Application to production of toxic proteins. Plasmid 69, 81-89 (2013).
Del Solar et al., Replication and Control of Circular Bacterial Plasmids, 1998 Microbio and Molec Biol. Rev 62:434-464.
Dickely, et al., Isolation of Lactococcus lactis nonsense suppressors and construction of a food-grade cloning vector (1995), Mol. Microbiol. 15:839-847).
Duenas et al., Novel helper phage design: intergenic region affects the assembly of bacteriophages and the size of antibody libraries, FEMS Microbiology Letters, 125 (1995) 317-322.
Engelberg-Kulka, et al., Addiction Modules and Programmed Cell Death and Antideath in Bacterial Cultures, Annu. Rev. Microbiol. 53 (1999) 43-70.
European Search Report dated Feb. 27, 2019, corresponding to corresponding European Application No. 18305781.9; 16 total pages.
Fems, Novel helper phage design: intergenic region affects the assembly of bacteriophages and the size of antibody libraries, Microbiol Lett (1995) 125, 317-321.
Fiedler, et al., proBA complementation of an auxotrophic E. coli strain improves plasmid stability and expression yield during fermenter production of a recombinant antibody fragment (2001) Gene 274: 111-118).
Fonfara, I., et al. (2014). Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. Nucleic Acids Research 42, 2577-2590.
Garneau Jr, et al., PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data, Scientific Reports 2017 7(1):8292.
Groenen, et al., Mapping of a Site for Packaging of Bacteriophage Mu DNA, Virology 144:520-522 (1985).
Gunther, et al. (1993). High efficiency, restriction-deficient in vitro packaging extracts for bacteriophage lambda DNA using a new E. coli lysogen. NAR 21(16) : 3903-3904.
Hashimoto, et al., DNA Sequences Necessary for Packaging Bacteriophage T3 DNA, Virology 187:788-795 (1992).
Henkel, et al., Toxins from Bacteria in EXS. 2010; 100: 1-29.
Hohn, DNA sequences necessary for packaging of bacteriophage DNA, Proc. Natl. Acad. Sci. USA, vol. 80, pp. 7456-7460 (1983).
Hohn, et al., (1977). Packaging recombinant DNA molecules into bacteriophage particles in vitro. PNAS 74(8): 3259-3263.
Jestin, et al., Improving the display of proteins on filamentous phage, Res. Microbiol, 152 (2001) 187-191.
Jiang et al., CRISPR-assisted editing of bacterial genomes, 2013, Nat Biotechnol 31, 233-239.
Kanhere, et al., A novel method for prokaryotic promoter prediction based on DNA stability, BMC Bioinformatics 2005, 6:1.
Koonin, E., et al. (2017). Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol 37, 67-78.
Kramer, et al., A novel helper phage that improves phage display selection efficiency by preventing the amplification of phages without recombinant protein, Nucleic Acids Research, ; (2003), vol. 31, No. 11 e59.
Krom et al., "Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies," Nano Letters, vol. 15, No. 7, Jul. 8, 2015; pp. 4808-4813.
Krupovic, M., et al. (2015). Taxonomy of prokaryotic viruses: update from the ICTV bacterial and archaeal viruses subcommittee. Arch Virol 161, 1095-1099.
Kues, et al., Replication of Plasmids in Gram-Negative Bacteria, U Microbiol Rev 53:491-516 (1989).
Lu et al., "Engineered Bacteriophage Targeting Gene Networks as Adjuvants for Antibiotic Therapy," Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, US, vol. 106, No. 12, Mar. 24, 2009; pp. 4629-4634.
Ma et al., Scientific Reports, Feb. 2, 2018; 8:2326. (Year: 2018). *
Mead, et al., Chimeric Single-Stranded DNA Phage-Plasmid Cloning Vectors, Biotechnology 10, 85-102 (1988).
Miwa, et al., Identification of sequences necessary for packaging DNA into lambda phage heads, Gene 20:267-279 (1982).
Needleman, et al., A general method applicable to the search for similarities in the amino acid sequence of two proteins, Journal of Molecular Biology, 48, 443-453 (1970).
Nilssen, et al., DeltaPhage—a novel helper phage for high-valence pIX phagemid display, Nucleic Acids Research, (2012) vol. 40, No. 16 e120.
Petri, et al., Isolation of fragments with pac function for phage P22 from phage LP7 DNA and comparison of packaging gene 3 sequences, Gene 88:47-55 (1990).
Pires et al., "Genetically Engineered Phages: a Review of Advances over the Last Decade," Microbiology and Molecular Biology Reviews, vol. 80, No. 3, Jun. 1, 2016; pp. 523-543.
Rakonjac, et al., Filamentous phage infection-mediated gene expression: construction and propagation of the gIII deletion mutant helper phage R408d3, Gene, (1997) 198, 99-103.
Rondot, et al., A helper phage to improve single-chain antibody presentation in phage display, Nature Publishing Group, (2001) 19, 75-78.
Russel et al., Genetic Analysis of the Filamentous Bacteriophage packaging Signal and of the Proteins That Interact with It, J Virol, 63:3284-3295 (1989).
Silver, et al., Bacterial Heavy Metal Resistance: New Surprises, Annu. Rev. Microbiol. 50 (1996) 753-789.
Soltes, et al., A new helper phage and phagemid vector system improves viral display of antibody Fab fragments and avoids propagation of insert-less virions, J Immunol Methods (2003) 274, 233-244.
Struhl, et al., Functional genetic expression of eukaryotic DNA in Escherichia coli (1976) PNAS USA 73; 1471-1475.
Wang, et al., Cloning of Genes that Suppress an Escherichia coli K-12 Alanine Auxotroph When Present in Multicopy Plasmids, Journal of Bacteriology, (1987), p. 5610-5614.
Westwater et al, "Use of Genetically Engineered Phage to Deliver Antimicrobial Agents to Bacteria: An Alternative Therapy for Treatment of Bacterial Infections," Antimicrobial Agents and Chemotherapy, American Society for Microbiology, US, vol. 47, No. 4, Apr. 1, 2003; pp. 1301-1307.
Westwater et al., "Development of a P1 Phagemid System for the Delivery of DNA into Gram-negative Bacteria," Journal of General Microbiology, vol. 148, No. 4, Apr. 1, 2002; pp. 943-950.
Wu, et al., The DNA site utilized by bacteriophage P22 for initiation of DNA packaging, Molec Microbiol 45:1631-1646 (2002).
Ziermann et al., "Characterization of the cos Sites of Bacteriophages P2 and P4," Gene, vol. 96, No. 1, Jan. 1, 1990; pp. 9-15.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11952594B2 (en) 2018-06-20 2024-04-09 Eligo Bioscience Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof
US20230233299A1 (en) * 2022-01-27 2023-07-27 EdgeEndo, LLC Dental, endodontic, and periodontic treatment methods and systems

Also Published As

Publication number Publication date
US20210380953A1 (en) 2021-12-09
DE19732334T1 (de) 2021-09-30
DE18305781T1 (de) 2020-09-17
US20190390175A1 (en) 2019-12-26
US11952594B2 (en) 2024-04-09
DK3810765T1 (da) 2021-08-23
WO2019243373A1 (en) 2019-12-26
EP3810765A1 (en) 2021-04-28
EP3584316A1 (en) 2019-12-25
EP3584316B1 (en) 2024-04-03
DK3584316T1 (da) 2020-08-03
US20240209326A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
US11124776B2 (en) Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof
US11946056B2 (en) Optimized vector for delivery in microbial populations
US11512116B2 (en) Chimeric receptor binding proteins for use in bacterial delivery vehicles
US11208437B2 (en) Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles
US11746352B2 (en) Microbiome modulation of a host by delivery of DNA payloads with minimized spread
US11970716B2 (en) Transcriptional control in prokaryotic cells using DNA-binding repressors
WO2020128108A1 (en) Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles
US20220064223A1 (en) Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles
WO2022144381A1 (en) Microbiome modulation of a host by delivery of dna payloads with minimized spread
US12098372B2 (en) Microbiome modulation of a host by delivery of DNA payloads with minimized spread
US20230134572A1 (en) Chimeric receptor binding proteins resistant to proteolytic degradation
EP4271808A1 (en) Microbiome modulation of a host by delivery of dna payloads with minimized spread

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: ELIGO-BIOSCIENCE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DECRULLE, ANTOINE;DUPORTET, XAVIER;STZEPOURGINSKI, IGOR;SIGNING DATES FROM 20190918 TO 20190920;REEL/FRAME:050582/0460

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

AS Assignment

Owner name: ELIGO BIOSCIENCE, FRANCE

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME AND ADDRESS PREVIOUSLY RECORDED AT REEL: 050582 FRAME: 0460. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:DECRULLE, ANTOINE;DUPORTET, XAVIER;STZEPOURGINSKI, IGOR;SIGNING DATES FROM 20190918 TO 20190920;REEL/FRAME:057263/0675

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PTGR); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

CC Certificate of correction